DRweb.med.u-szeged.hu/phcol/mktrs/bibl/varropubl.doc · Web viewDr. Varró András közleményeinek...
77
DR. VARRÓ ANDRÁS KÖZLEMÉNYEINEK TELJES LISTÁJA 1. Folyóiratban megjelent közlemények 1. Csaba G., Inczefi-Gonda A., Dobozy O., Varró A., Rabloczky G.: Impact of neonatal treatment with cardioactive glycosides (digoxin, ouabain) on receptor binding capacity, blood level and cardiac function in the adult rat, extension of the imprinting theory. Gen. Pharmacol. 14: 709-711, 1983. Impact factor (1983): 0.988 2. Varró A., Elharrar V., Surawicz B.: Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers. J. Cardiovasc. Pharmacol. 7: 482-492, 1985. Impact factor (1985): 2.190 3. Varró A., Elharrar V., Surawicz B.: Effect of antiarrhythmic drugs on the premature action potential duration in canine cardiac Purkinje fibers. J. Pharmacol. Exp. Ther. 223: 304-311, 1985. Impact factor (1985): 3.630 4. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Use-dependent effects of amiodarone on V max in cardiac Purkinje and ventricular muscle fibers. Eur. J. Pharmacol. 112: 419-422, 1985. Impact factor (1985): 3.182 5. Varró A., Rabloczky G., Jaksics K.: Különböző antiaritmiás szerek védőhatásainak öszehasonlító vizsgálata egér akonitin- aritmiában. Kísérl. Orvostud. 37: 207-212, 1985. Impact factor (1985): - in Hungarian language 6. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Effect of antiarrhythmic drugs on the cycle lenght-dependent action potential duration in dog Purkinje and ventricular muscle fibers. J. Cardiovasc. Pharmacol. 8: 178-185, 1986. Impact factor (1986): 2.184 1
Transcript of DRweb.med.u-szeged.hu/phcol/mktrs/bibl/varropubl.doc · Web viewDr. Varró András közleményeinek...
DR. VARRÓ ANDRÁS KÖZLEMÉNYEINEK TELJES LISTÁJA
1. Folyóiratban megjelent közlemények
1. Csaba G., Inczefi-Gonda A., Dobozy O., Varró A., Rabloczky G.: Impact of neonatal treatment with cardioactive glycosides (digoxin, ouabain) on receptor binding capacity, blood level and cardiac function in the adult rat, extension of the imprinting theory.Gen. Pharmacol. 14: 709-711, 1983. Impact factor (1983): 0.988
2. Varró A., Elharrar V., Surawicz B.: Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers.J. Cardiovasc. Pharmacol. 7: 482-492, 1985.Impact factor (1985): 2.190
3. Varró A., Elharrar V., Surawicz B.: Effect of antiarrhythmic drugs on the premature action potential duration in canine cardiac Purkinje fibers.J. Pharmacol. Exp. Ther. 223: 304-311, 1985.Impact factor (1985): 3.630
4. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers.Eur. J. Pharmacol. 112: 419-422, 1985.Impact factor (1985): 3.182
5. Varró A., Rabloczky G., Jaksics K.: Különböző antiaritmiás szerek védőhatásainak öszehasonlító vizsgálata egér akonitin-aritmiában.Kísérl. Orvostud. 37: 207-212, 1985.Impact factor (1985): - in Hungarian language
6. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Effect of antiarrhythmic drugs on the cycle lenght-dependent action potential duration in dog Purkinje and ventricular muscle fibers.J. Cardiovasc. Pharmacol. 8: 178-185, 1986.Impact factor (1986): 2.184
7. Varró A., Rabloczky G.: Antiarrhythmic effect of acute and chronic amiodarone treatment in conscious rats.J. Pharm. Pharmacol. 38: 772 -773, 1986.Impact factor (1986): 1.404
8. Varró A., Elharrar V., Surawicz B.: Antiaritmiás anyagok frekvenciafüggő hatásai az akciós potenciálok időtartamára kutya Purkinje és kamra munkaizomrostjain.Kísérl. Orvostud. 38: 113-124, 1986.Impact factor (1986): - in Hungarian language
9. Varró A., Surawicz B., Elharrar V.: Antiaritmiás anyagok hatása a korai extraszisztolek által létrejött diszperzió mértékére.Kísérl. Orvostud. 38: 572-591, 1986.Impact factor (1986): - in Hungarian language
1
10. Varró A., Elharrar V., Surawicz B.: Néhány I osztályba tartozó antiaritmiás anyag frekvenciafüggő hatása a depolarizáció maximális sebességére kutyaszív Purkinje és kamrai munkaizomrostjain.Kísérl. Orvostud. 38: 133-149, 1986.Impact factor (1986): - in Hungarian language
11. Zubovics Z., Toldy L., Varró A., Rabloczky G., Kürthy M., Dvortsak P., Jerkovich G., Tomori E.: Synthesis and antiarrhythmic activity of N-aryl alkylenediamines.Eur. J. Med. Chem./Chim. Ther. 21: 370-378, 1986.Impact factor (1986): 0.778
12. Nánási P.P., Varró A., Rabloczky G., Danko M.: Use-dependent blockade of sodium channels induced by bencyclane in frog sketetal muscle and canine cardiac Purkinje fiber.Arch. Int. Pharmacodyn. Ther. 290: 278-287, 1987.Impact factor (1987): 0.827
13. Varró A., Bodi I., Rabloczky G.: Antiarrhythmic effect of desethylamiodarone in conscious rats.J. Pharm. Pharmacol. 39: 483-84, 1987.Impact factor (1987): 1.174
14. Varró A., Rabloczky G., Jaszlits L., Kürthy M., Zubovics Z., Toldy L.: Pharmacological investigation of a new antiarrhythmic agent GYKI-23 107.Drugs Exp. Clin. Res. 8: 21-28, 1987.Impact factor (1987): 0.514
15. Varró A., Saitoh H. , Surawicz B.: Effects of antiarrhythmic drugs on premature action potential duration in canine ventricular muscle fibers.J. Cardiovasc. Pharmacol. 10: 407-414, 1987.Impact factor (1987): 1.831
16. Szathmary J.L., Rabloczky G., Kürthy M., Varró A., Solti F.: Electrophysiological effects of the antiarrhythmic agent GYKI 23 107 in dogs.Acta Med. Hung. 45: 209-219, 1988.Impact factor (1988): 0.051
17. Varró A., Németh M., Rablóczky Gy., Papp J.Gy., Szekeres L.: Electrophysiological effects of GYKI-23107, a new antiarrhythmic compound, in isolated rabbit and canine cardiac preparations.J. Cardiovasc. Pharmacol. 11: 251-257, 1988. Impact factor (1988) : 2.047
18. Varró A., Nakaya Y., Elharrar V., Surawicz B.: The effects of amiodarone on repolarization and refractoriness of cardiac fiber.Eur. J. Pharmacol. 154: 11-18, 1988.Impact factor (1988): 3.172
19. Varró A., Bodi I., Jednakovits A., Rabloczky G.: Frequency- dependent effects of class I, III and IV antiarrhythmic drugs on the conduction and excitability in rabbit ventricular muscle.Arch. Int. Pharmacodyn. Ther. 292: 157-165, 1988.Impact factor (1988): 1.014
2
20. Varró A., Nakaya Y., Surawicz B.: Az amiodaron intracellularis szívelektrofiziológiai hatásainak elemzése.Cardiol. Hung. 18 E: 57-65, 1988.Impact factor (1988): - in Hungarian language
21. Lathrop D.A., Varró A., Schwartz A.: Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol.Eur. J. Pharmacol. 164: 487-496, 1989.Impact factor (1989): 3.370
22. Lathrop D.A., Varró A., Gaum W.E., Kaplan S.: Age-related changes in electromechanical properties of canine ventricular muscle: effect of ouabain.J. Cardiovasc. Pharmacol. 14: 681-687, 1989.Impact factor (1989): 2.151
23. Lathrop D.A., Varró A.: Modulation of the effects of sotalol on Purkinje stand electromechanical characteristics.Can. J. Physiol. Pharmacol. 67: 1463-1467, 1989.Impact factor (1989): 0.666
24. Nakaya Y., Varró A., Elharrar V., Surawicz B.: Effect of altered repolarization course induced by antiarrhythmic drugs and constant current pulses on the duration of premature action potentials in canine cardiac Purkinje fibers.J. Cardiovasc. Pharmacol. 14: 908-919, 1989.Impact factor (1989): 2.151
25. Jednákovits A., Bódi I., Varró A., Rabloczky G.: Néhány I., III. és IV. osztályba tartozó antiaritmiás anyag frekvenciafüggô hatásainak vizsgálata az ingerületvezetésre és az ingerküszöbre nyúlak szívének jobb kamrai izomrostjain.Kisérl. Orvostud. 41: 241-246, 1989.Impact factor (1989): - in Hungarian language
26. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Frequency-dependent and independent effects of tetrodotoxin on Vmax in cardiac fibers.Acta Physiol. Hung. 73: 47-52, 1989.Impact factor (1989): 0.236
27. Lathrop D.A., Nanasi P.P., Varró A.: In vitro models of dog Purkinje fibre triggered and spontaneous electrical activity: Effects of nicorandil.Br. J. Pharmacol. 99: 119-123, 1990.Impact factor (1990): 4.666
28. Lathrop D.A., Varró A.: The combined electrophysiological effects of lidocaine and sotalol in isolated canine cardiac Purkinje fibers are rate-dependent.Br. J. Pharmacol. 99: 124-130, 1990.Impact factor (1990): 4.666
29. Varró A., Lathrop D.A.: Sotalol and mexiletine: combination of rate dependent electrophysiological effects.J. Cardiovasc. Pharmacol. 16: 557-567, 1990.Impact factor (1990): 2.368
3
30. Nánási P.P., Varró A., Lathrop D.A., Danko M.: Use-dependent action of antiarrhythmic drugs in frog skeletal muscle and canine Purkinje fiber.Gen. Pharmacol. 21: 747-51, 1990.Impact factor (1990): 1.227
31. Varró A., Lathrop D.A., Surawicz B.: Effects of propanolol on premature action potentials in canine Purkinje and ventricular muscle.J. Cardiovasc. Pharmacol. 16: 757-763, 1990.Impact factor (1990): 2.368
32. Varró A., Lathrop D.A., Knilans T.K., Nanasi P.P., Rabloczky G.: Concentration- and rate-dependent effects of restacorin (B-GYKI-38 233) on isolated canine Purkinje fibers.Naunyn-Schmiedeberg's Arch. Pharmacol. 342: 691-697, 1990.Impact factor (1990): 3.349
33. Knilans T.K., Varró A., Nánási P.P., Murray R.J., Kaiser F.C., Lathrop D.A.: Electrophysiological effect of FPL 13210 on canine Purkinje fibers action potential duration and Vmax: comparison to disopyramide.Cardiovasc. Drugs Ther. 5: 139-146, 1991.Impact factor (1991): 0.519
34. Knilans T.K., Lathrop D.A., Nanasi P.P., Schwartz A., Varró A.: Rate and concentration-dependent effects of UK-68 798, a potent new class III antiarrhythmic, on canine Purkinje fiber action potential duration and Vmax.Br. J. Pharmacol.103: 1568-1572, 1991.Impact factor (1991): 4.786
35. Varró A., Nanasi P.P., Lathrop D.A.: Effect of sotalol on transmembrane ionic currents responsible for repolarization in cardiac ventricular myocytes from rabbit and guinea pig.Life Sci. 48: Pl 7-Pl 12, 1991.Impact factor (1991): 1.766
36. Varró A., Nanasi P.P., Lathrop D.A.: Voltage-clamp characteristics of rabbit ventricular myocytes.Cardioscience 2: 233-243, 1991.Impact factor (1991): 0.762
37. Nanasi P.P., Knilans T.K., Varró A., Murphy A.M., Fujiki A., Schwartz A., Lathrop D.A.: Active and passive electrical properties of isolated canine cardiac Purkinje fibers under conditions of simulating ischaemia.: Effect of diltiazem.Pharmacol. & Toxicol. 71: 52-56, 1992.Impact factor (1992): 0.992
38. Nanasi P.P., Knilans T.K., Richards I.S., Varró A., Lathrop D.A.: Biphasic effect of tetraethylammonium on canine Purkinje fibers action potential configuration.Gen. Pharmacol. 23: 733-738, 1992.Impact factor (1992): 0.885
39. Nanasi P.P., Varró A., Lathrop D.A.: Ionic currents in ventricular myocytes isolated from the heart of a patient with idiopathic cardiomyopathy.Cardioscience 3: 85-89, 1992.Impact factor (1992): 0.911
4
40. Nanasi P.P., Danko M., Varró A., Lathrop D.A.: Nonlinear relationship between Vmax and h during repetitive electrical activity of skeletal muscle.Gen. Phys. Biophys. 11: 159-167, 1992.Impact factor (1992): 0.573
41. Varró A., Papp J.Gy.: The impact of single cell voltage clamp on the understanding of cardiac ventricular action potential.Cardioscience 3:131-144, 1992.Impact factor (1992): 0.911
42. Nanasi P.P., Varró A., Lathrop D.A.: Isolation of human ventricular and atrial cardiomyocytes.Cardioscience 4:111-116, 1993.Impact factor (1993): 0.900
43. Varró A., Lathrop D.A., Hester B., Nanasi P.P., Papp J.Gy.: Ionic currents and action potentials in rabbit, rat, and guinea pig ventricular myocytes.Basic Research Cardiol. 88: 93-102, 1993.Impact factor (1993): 0.991
44. Varró A., Negretti N., Hester S.B., Eisner D.A.: An estimate of the calcium content of the sarcoplasmic reticulum in rat ventricular myocytes.Pflügers Arch. Eur. J. Physiol. 423: 158-160, 1993.Impact factor (1993): 2.715
45. Varró A., Hester S., Papp J.Gy.: Caffeine decreases the inward rectifier potassium and the inward calcium currents in rat ventricular myocytes.Br. J. Pharmacol. 109: 895-897, 1993.Impact factor (1993): 5.270
46. Varró A., Nanasi P.P., Lathrop D.A.: Potassium currents in isolated human atrial and ventricular cardiocytes.Acta Physiol. Scand. 149: 133-142, 1993.Impact factor (1993): 1.621
47. Lathrop D.A., Nanasi P.P., Schwartz A., Varró A.: Ionic basis for OPC 8212- induced increase in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes.Eur. J. Pharmacol. 240: 127-137, 1993.Impact factor (1993): 2.849
48. Érczi I., Rablóczky G., Varró A., Somogy G., Kürthy M., Bódi I.: Synthesis and anti-arrhythmic activity of aminoguanidine derivates.Eur. J. Med. Chem./Chim. Ther. 28: 185-193, 1993.Impact factor (1993): 0.716
49. Hála O., Németh M., Varró A., Papp J.Gy.: Electrophysiological effects of detajmium on isolated dog cardiac ventricular and Purkinje fibers.J. Cardiovasc. Pharmacol. 24: 559-565, 1994.Impact factor (1994): 1.680
5
50. Nánási P.P., Varró A., Bryant S.H., Lathrop D.A.: Effects of veratrine on ion currents in single rabbit cardiomyocytes.Gen. Pharmacol. 25: 1667-1672, 1994.Impact factor (1994): 0.846
51. Nánási P.P., Varró A., Lathrop D.A., Bryant S.H.: Effects of veratrine on Na and Ca currents in frog skeletal muscle.Gen. Pharmacol. 25: 1661-1666, 1994.Impact factor (1994): 0.846
52. Németh M., Varró A., Papp J.Gy.: Electrophysiological effects of tiracizin and its metabolites in dog cardiac Purkinje fibers.Gen. Pharmacol. 26: 793-798, 1995.Impact factor (1995): 0.871
53. Varró A., Fazekas T., Papp J.Gy.: Amiodarone 1994.Cardiol. Hung. 24: 5-17, 1995.Impact factor (1995): - in Hungarian language
54. Negretti N., Varró A., Eisner D.A.: Estimate of net calcium fluxes and sarcoplasmic reticulum calcium content during systole in rat ventricular myocytes.J. Physiol. (London) 486: 581-591, 1995.Impact Factor (1995): 4.327
55. Varró A., Papp J.Gy.: Classification of positive inotropic actions based on electrophysiological characteristics: Where should calcium sensitizer be placed?J. Cardiovasc. Pharmacol. 26: S32-S44, 1995. Impact factor (1995): 1.709
56. Németh M., Virág L., Hála O., Varró A., Kovács G., Thormählen D., Papp J.Gy.: The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers.Cardiovasc. Res. 31: 246-248, 1996. Impact factor (1996): 3.263
57. Pankucsi C., Varró A., Kovács L., Nánási P.P.: Three distinct components of the negative inotropic action of lidocaine in dog Purkinje fiber.Gen. Pharmacol. 27: 69-71, 1996.Impact factor (1996): 0.818
58. Virág L., Hála O., Marton A., Varró A., Papp J.Gy.: Cardiac electrophysiological effects of Levosimendan a new calcium sensitizer. Gen. Pharmacol. 27: 551-556, 1996.Impact factor (1996): 0.818
59. Lathrop D.A., Varró A., Nánási P.P., Bódi I., Takyi E., Pankucsi Cs.: Differences in the effects of d- and dl-sotalol on isolated human ventricular muscle electromechanical activity after beta-adrenoceptor stimulation.J. Cardiovasc. Pharmacol. Therapeut. 1: 65-74, 1996. Impact factor (1996): -
60. Lathrop D.A., Nánási P.P., Varró A., Schwartz A.: Comparison of the electromechanical effects of vesnarinone and amrinone in isolated dog Purkinje strands and ventricular trabeculae.
6
J. Cardiovasc. Pharmacol. Therapeut. 1: 133-40, 1996. Impact factor (1996): -
61. Varró A., Virág L., Papp J.Gy.: Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in isolated rabbit cardiac myocytes.Br. J. Pharmacol. 117: 1181-1186, 1996. Impact factor (1996): 4.075
62. Szigligeti P., Pankucsi C., Bányász T., Varró A., Nánási P.P.: Action potential duration and force-frequency relationship in isolated rabbit, guinea pig and rat cardiac muscle.J. Comp. Physiol. B. 166: 150-155, 1996. Impact factor (1996): 0.926
63. Nánási P.P., Varró A., Pankucsi C., Homolay P., Knilans T.K., Kovács L., Papp J.Gy., Lathrop D.A.: Electrical restitution in diseased human ventricular myocardium.Clin. Physiol. 16: 339-351, 1996 Impact factor (1996): 0.576
64. Nánási P.P., Pankucsi C., Bányász T., Szigligeti P., Papp J.Gy., Varró A.: Electrical restitution in rat ventricular muscle.Acta Physiol. Scand. 158: 143-153, 1996. Impact factor (1996): 1.519
65. Leprán I., Baczkó I., Varró A., Papp J.GY.: ATP-sensitive potassium channel modulators: Both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats.J. Pharmacol. Exp. Ther. 227: 1215-1220, 1996. Impact factor (1996): 3.432
66. Papp J.Gy., Németh M., Krassói I., Mester L., Hála O., Varró A.: Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle.J. Cardiovasc. Pharmacol. Therapeut. 1: 287-296, 1996. Impact factor (1996): -
67. Baláti B., Varró A., Papp J.Gy.: A cibenzolin, az almokalnt és az amiodaron elektrofiziológiai hatásainak összehasonlító vizsgálata kutyaszívbôl izolált jobb kamrai trabekuláris izmon.Cardiol. Hung. 25: 19-23, 1996. Impact factor (1996): - in Hungarian language
68. Pankucsi C., Bányász T., Magyar J., Gyönös I., Kovács A., Szénási A., Szénási G., Varró A., Nánási P.P.: Electrophysiological effects of EGIS-72209 a new antiarrhythmic agent, in isolated guinea pig papillary muscle.Gen. Pharmacol. 29: 275-280, 1997. Impact factor (1997) : 1.056
69. Pankucsi C., Bányász T., Magyar J., Gyönös I., Kovács A., Varró A., Szénási G., Nánási P.P.: Electrophysiological effects of EGIS-72209, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissue.Naunyn-Schmiedeberg Arch. Pharmacol. 355: 398-405, 1997. Impact factor (1997): 2.492
7
70. Bányász T., Magyar J., Szigligeti P., Pankucsi Cs., Varró A., Nánási PP.: Frequency-dependent characteristics of human cardiac muscle.Exp. Clin. Cardiol. 2: 205-209, 1997.Impact factor (1997): -
71. Németh M., Varró A., Thormählen D., Papp J,Gy.: Tedisamil is a potent blocker of ATP sensitive potassium channels in cardiac muscle.Expl. Clin. Cardiol. 2: 37-40, 1997 Impact factor (1997): -
72. Németh. M., Varró A., Virág L., Hála O., Thormählen D., Papp J.Gy.: Freaquency dependent cardiac electrophysiologic effects of tedisamil: Comparison with quinidine and sotalol.J. Cardiovasc. Pharmacol. Therapeut. 4: 273-284, 1997. Impact factor (1997): -
73. Mátyus P., Varró A., Papp J.Gy., Wamhoff H., Varga I., Virág L.: Antiarrhythmic agents: Current status and perspectives.Med. Research Review 17: 427-451, 1997. Impact factor (1997): 5.116
74. Fazekas T., Varró A., Papp J.Gy.: A klinikai arrhythmiák gyógyszeres kezelésének jelenlegi helyzete és perspektívái.Cardiol. Hung. 26: 67-77, 1997. Impact factor (1997): - in Hungarian language
75. Krassói I., Fazekas T., Katona A., Liszkai G., Varró A., Papp J.Gy.: Erythromycin által elôidézett korai utódepolarizóció megszüntetése mexiletinnel.Cardiol. Hung. 26: 173-177, 1997. Impact factor (1997): - in Hungarian language
76. Mátyus P., Borosy A.P., Varró A., Papp J.Gy. Barlocco D., Cignarella G.: Development of pharmacophores for inhibitors of the rapid component of the cardac delayed rectifier potassium current.Int. J. Quant. Chem. 69: 21-30, 1998. Impact factor (1998): 1.270
77. Fazekas T., Krassói I., Lengyel Cs., Varró A., Papp J.Gy.: Suppression of erythromycin-induced early after-depolarization and torsade de pointes ventricular tachycardia by mexiletine.PACE 21: 147-150, 1998.Impact factor (1998): 1.301
78. Virág L., Varró A., Papp J.Gy.: Effect of disopyramide on potassium currents in rabbit ventricular myocytes.Naunyn-Schmiedeberg Arch. Pharmacol. 357: 268-275, 1998. Impact factor (1998): 2.200
79. Nánási P.P., Varró A., Lathrop D.A.: Action potential duration and contractility in canine cardiac tissue: Action of inotropic drugsGen. Pharmacol. 31:415-418, 1998. Impact factor: (1998): 1.037
8
80. Baláti B., Varró A., Papp J.Gy.: Comparison of the cellular electrophysiological characteristics of canine left ventricular epicardium, M cells, endocardium and Purkinje fibres.Acta Physiol Scand. 164: 181-190, 1998. Impact faktor: (1998) 1.258
81. Baláti B., Varró A., Papp Gy.: Az M sejtek elektrofiziológiai jellemzése: élettani, farmakológiai és klinikai jelentőségük.Cardiol. Hung. 27: 155-164, 1998.Impact factor (1998): - in Hungarian language
82. Iost N., Virág L., Opincariu M., Szécsi J., Varró A., Papp J.Gy.: Delayed rectifier potassium current in indiseased human ventricular myocytes.Cardiovasc. Res. 40, 508-515, 1998.Impact factor (1998): 2.996
83. Szigligeti P., Bányász T., Magyar J., Szigeti G., Papp Z., Varró A., Nánási P.P.: Intracellular calcium and electrical restitution in mammalian cardiac cells.Acta Physiol. Scand. 163(2):139-147, 1998.Impact factor (1998): 1.258
84. Kovesdi I, Dominguez-Rodriguez MF, Orfi L, Naray-Szabo G, Varró A., Papp JG, Matyus P.: Application of neural networks in structure-activity relationships.Med. Res. Rev. 19:249-269, 1999. Impact factor (1999): 2.514
85. Banyasz T, Magyar J, Varró A., Kovacs A, Gyonos I, Szenasi G, Nanasi PP.: EGIS-7229, the new combined class III antiarrhythmic agent: lack of EAD inducing effect.Gen Pharmacol. 32:329-333., 1999. Impact factor (1999): 1.105
86. Balati B, Varró A., Papp JG.: Pharmacological modification of the dispersion of repolarization in the heart: importance of the M cells.Cardiovasc Drugs Ther. 13: 491-505, 1999Impact factor (1999): 1.135
87. Varró A.: Új elméleti lehetőségek amiodaron-szerű és egyéb antiaritmiás hatású gyógyszerek fejlesztésére.Cardiol. Hung. 28 Suppl.1: 50-56, 1999. Impact factor (1999): - in Hungarian language
88. Matyus P, Rettegi T, Varró A., Papp JGy.: New antiarrhythmic agents: a conceptually novel approach.Med Res Rev. 20: 294-303, 2000. Impact factor (2000): 3.417
89. Virág L., Fazekas T., Iost N., Varró A., Berlin K.D., Scherlag B.J., Lazzara R., Papp J.Gy.: Effect of GLG-V-13, a class III antiarrhythmic agent, on potassium currents in rabbit ventricular myocytes.Life Sciences 66: PL 253-258, 2000.Impact factor (2000): 1.808
9
90. Varró A., Baláti B., Iost N., Takács J., Virág L., Lathrop D.A., Lengyel C., Tálosi L., Papp J.Gy.: The role of IKs in dog ventricular muscle and Purkinje fibre repolarisationJ. Physiol. (London) 523: 67-81, 2000.Impact factor (2000): 4.455
91. Baláti B., Iost N., Simon J., Varró A., Papp J.Gy.: Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agent, in canine isolated ventricular muscle and Purkinje fibres.Gen Pharmacol. 34: 85-93, 2000.Impact factor (2000): 1.140
92. Baczkó I., El-Reyani N.E., Farkas A., Virág L., Iost N., Leprán I., Mátyus P., Varró A., Papp J.Gy.: Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.Eur. J. Pharmacol. 404: 181-190, 2000.Impact factor (2000): 2.236
93. Fazekas T., Virág L., Iost N., Varró A., Scherlag B.J., Patterson E., Lazzara R., Papp Gy.:Egy új tipusú, repolarizációt megnyújtó antiarrhythmiás vegyület, a GLG-V-13, celluáris és ioncsatornaszintű elektrofiziológiai jellemzése.Cardiol. Hung. 29: 241-249, 2000.Impact factor (2000): - in Hungarian language
94. Magyar J., Iost N., Körtvély Á.., Bányász T., Virág L., Szigligeti P., Varró A., Opincariu M., Szécsi J., Papp J.Gy., Nánási P.P.: Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytesPflüg. Arch. Eur. J. Physiol. 441: 144-149, 2000.Impact factor (2000): 2.203
95. Takács J., Lengyel Cs., Varró A., Papp Gy.: A késői egyenirányító káliumáram gyors és lassú komponensét egyaránt gátló azimilide hatása kutyaszív kamrai munkaizom és purkinje rostjaira.Cardiol. Hung. 29: 227-234, 2000.Impact factor (2000): - in Hungarian language
96. Lengyel Cs., Iost N., Virág L., Varró A., Lathrop D.A., Papp J.Gy.: Pharmacological block of the slow component of the outward delayed rectifier current (IKs) fails to lengthen rabbit ventricular muscle QTc and action potential duration.Br. J. Pharmacol. 132: 101-110, 2001.Impact factor (2001): 3.502
97. Lengyel Cs., Iost N., Virág L., Lathrop D.A., Varró A., Papp J.Gy.: A késői egyenirányító kálium áram lassú komponensének (IKs) blokkolása, a gyors komponens (IKr) gátlásával ellentétben, nem nyújtja meg a kamrai repolarizációt nyúlszív preparátumokon.Cardiol. Hung. 31: 193-202, 2001.Impact factor (2001): - in Hungarian language
98. Virág L., Iost N., Opincariu M., Szécsi J., Bogáts G., Szenohradszky P., Varró A., Papp J.Gy.: The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes.
10
Cardiovasc. Res. 49: 790-797, 2001.Impact factor (2001): 4.552
99. Varró A., Takács J., Németh M., Hála O., Virág L., Iost N., Balati B., Ágoston M., Vereckei A., Pastor G., Delbruyčre M., Gautier P., Nisato D., Papp J.Gy.: Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol. 133: 625-634, 2001.Impact factor (2001): 3.502
100. Varró A., Lathrop D.A., Papp J.Gy.: Letters to the editor. Role of the delayed rectifier component IKs in cardiac repolarization.J. Cardiovasc. Electrophysiol. 12: 1204-1205, 2001.Impact factor (2001): 2.976
101. Villa S., Barlocco D., Cignarella G., Papp J.Gy., Baláti B., Varró A., Borosy A., Kerserű K., Mátyus P.: 3,8-diazabicyclo-[3.2.1]-octane derivatives as analogues of ambasilide, a class III antiarrhythmic agent.Eur. J. Med. Chem. 36:495-506, 2001. Impact factor (2001): 1.077
102. Almeida D.R.P., Pisterzi L.F., Chass G.A., Torday L., Varró A., Papp J.Gy., Csizmadia I.G.:Density functional molecular study on the full conformational space of the S-4-(2-Hydroxypropoxy) carbazol fragment of carvedilol (1-(9H-Carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol) in Vacuum and in different solvent media.J. Physiol. Chem. A 106: 10423-10436, 2002.Impact factor (2002) = 2.765
103. Biliczki P., Virág L., Iost N., Papp J.Gy., Varró A.: Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve.Br. J. Pharmacol. 137: 361-368, 2002.Impact factor (2002): 3.450
104. Gasparro D.M., Almeida D.R.P., Dobo S.M., Torday L.L., Varró A., Papp J.Gy.: An ab initio and DFT conformational analysis of unsubstituted and -substituted ethyl-benzene: (Ph-CH2-CH2-Z; Z= -H, -F, -NH3+, -CH3).J. Mol. Structure (Theochem.) 585: 167-179, 2002.Impact factor (2002): 1.014
105. Koo J.C.P., Chass G.A., Perczel A., Farkas O., Torday L., Varró A., Papp J.Gy., Csizmadia I.G.: Exploration of the four-dimensional-conformational potential energy hypersurface on N-acetyl-L-aspartic acid N’-acetyl-L-aspartic acid N’-methylamide with its internally hydrogen bonded side-chain orientation.J. Physical Chemistry A. 106: 6999-7009, 2002.Impact factor (2002): 2.765
106. Koo J.C.P., Chass G.A., Perczel A., Farkas O., Varró A., Torday L., Papp J.Gy., Csizmadia I.G.: N-acetyl-L-aspartic acid-N’-methylamide with side-chain orientation capable of external hydrogen bonding.
11
Eur. Physical J. D. 20: 499-511, 2002.Impact factor (2002): 1.300
107. Koo J.C.P., Lam J.S.W., Salpietro S.J., Chass G.A., Enriz R.D., Torday L.,L., Varró A., Papp J.Gy.: How reliable could economic Hartree-Fock computations be in studying large, folded peptides? A comparative HF and DFT case study on N- and C-protected asparic acid.J. Mol. Structure (Theochem) 619: 143-197, 2002. Impact factor (2002): 1.014
108. Kun A., Pataricza J., Krassói I., Szécsi M., Hőhn J., Varró A., Papp J.Gy.: Low 4-aminopyridine concentration-induced contraction is mediated by neuronal noradrenaline in canine saphenous vein.Vascular Pharmacol. (Gen. Pharmacol.) 39: 7-11, 2002.Impact factor (2002): 0.591
109. Law J.M.S., Chass G.A., Torday L.L., Varró A., Papp J.Gy.: Molecular computations on lipids: a numbering system for phospholipids and triglyceride.J. Mol. Structure (Theochem) 619: 1-20, 2002.Impact factor (2002): 1.014
110. Mehdizadeh A., Chass G.A., Farkas O., Perczel A., Torday L., Varró A., Papp J.Gy.: Conformational effects of one glycine residue on the other glycine residues in the Ac-Gly-Gly-Gly-NHMe tripeptide motif: an ab initio exploratory study.J. Mol. Structure (Theochem) 588: 187-200, 2002.Impact factor (2002): 1.014
111. Magyar J., Szentandrássy N., Bányász T., Fülöp L., Varró A., Nánási P.P.: Effects of thymol on calcium and potassium currents in canine and human ventricular cardiomyocytes Br. J. Pharmacol. 136: 330-338, 2002.Impact factor (2002): 3.450
112. Opincariu M., Varró A, Iost N., Virág L., Hála O., Szolnoki J., Szécsi J., Bogáts G., Szenohradszky P., Mátyus P., Papp J.Gy.: The cellular electrophysiologic effect of a new amiodarone like antiarrhythmic drug GYKI 16638 in undiseased human ventricular muscle: comparison with sotalol and mexiletine.Current Med. Chem. 9: 41-46, 2002.Impact factor (2002): 4.966
113. Pisterzi L.F., Almeida D.R.P., Chass G.A., Torday L., Papp J.Gy., Varró A., Csizmadia I.G.:Density functional molecular computations on protonated serotonin in the gas phase and various solvent media.Chem. Phys. Letters 365: 542-551, 2002.Impact factor (2002): 2.526
114. Setiadi D.H., Chass G.A., Torday L.L., Varró A., Papp J.Gy.: Vitamin E models. Conformational analysis and stereochemistry of tetralin, chroman, thiochroman and selenochroman.J. Mol. Structure (THEOCHEM) 594: 161-172, 2002.Impact factor (2002): 1.014
12
115. Setiadi D.H. Chass G.A., Tordai L., Varró A., Papp J.Gy., Csizmadia I.G.: Vitamin E models – The effect of heteroatom substitution in 2-ethyl-2-methyl chroman and 2-ethyl-2-methyl-6-hydroxychroman.Eur. Physical J. D. 20: 609-618, 2002.Imact factor (2002): 1.300
116. Fazekas T., Csanádi Z., Varró A.: A pitvarfibrilláció patogenezise és klinikai jelentősége.Orvosi Hetilap: 144: 155-163, 2002.Impact factor (2002): - in Hungarian language
117. Almeida D.R.P., Gasparro D.M., Pisterzi L.F., Torday L.L., Varró A., Papp J.Gy., Penke B.Gas phase conformational basicity of carvedilol fragment B, 2(S)-1-(ethylamonium)propane-2-ol: An ab initio study on a protonophoretic of oxidative phosphorylation uncoupling.J. Mol. Sturcture (THEOCHEM) 631: 251-270, 2003.Impact factor (2002): 1.014
118.Andrássy G., Szabó A., Dunai A., Simon E., Nagy T., Trummer Z., Tahy A., Varró A.Acute effects of cigarette smoking on the QT interval in healthy smokers.Am. J. Cardiol. 92: 489-492, 2003.Impact factor (2002): 2.327
119. Bányász T., Fülöp L., Magyar J., Szentandrássy N., Varró A., Nánási P.P.: Endocardial versus epicardial differences in L-type calcium current in canine ventricular myoytes studied by action potential voltage clamp.Cardiovasc. Res. 58: 66-75, 2003.Impact factor (2002): 4.692
120. Csanádi Z., Fazekas T., Varró A.A pitvarfibrilláció kezelésének nem farmakológiai lehetőségei.Orvosi Hetilap 144: 1279-1289, 2003. Impact factor (2002): - in Hungarian language
121. Fazekas T., Csanádi Z., Varró A.A pitvarfibrilláció gyógyszeres kezelése.Orvosi Hetilap 144: 1199-1206, 2003.Impact factor (2002): - in Hungarian language
122. Fazekas T., Csanádi Z., Varró A.A pitvarfibrilláció patogenezise és klinikai jelentősége.Orvosi Hetilap 144: 155-163, 2003Impact factor (2002): - in Hungarian language
123. Iost N., Virág L., Varró A., Papp J.Gy.: Comparison of the effect of class I/A antiarrhythmic drugs on transmembrane potassium currents in rabbit ventricular myocytesJ. Cardiovasc. Pharmacol. & Ther. 8: 31-41, 2003.Impact factor (2002): 0
13
124. Koo J.C.P., Lam J.S.W., Chass G.A., Torday L.L., Varró A., Papp J.Gy.: Conformational dependence of the intrinsic acidity of the aspartic acid residue sidechain in N-acetyl-L-aspartic acid-N'-methylamide.J. Mol. Structure (THEOCHEM) 620: 231-255, 2003.Imact factor (2002): 1.014
125. Liao J.C.C., Chua J.C., Chass G.A., Perczel A., Varró A., Papp J.Gy.: An assessment of the chiral environment created by adjacent D- and L-alanyl residues on a glycine unit within the tripeptide N-Ac-Ala-Gly-Ala-NHMe: an ab initio exploratory study.J. Mol. Structure (THEOCHEM) 621: 163-187, 2003. Imact factor (2002): 1.014
126. Setiadi D.H., Chass G.A., Torday L.,L., Varró A., Papp J.Gy.: Vitamin E models. Can the anti-oxidant and pro-oxidant dichotomy of alpha-tocopherol be related to ionic ring closing and radical ring opening redox reactions?J. Mol. Structure (THEOCHEM) 620: 93-106, 2003.Imact factor (2002): 1.014
127.Steenman M., Chen Y.W., Le Cunff M., Lamirault G., Varró A., Hoffmann E., Léger J.J.: Transcriptomal analysis of failing and non-failing human hearts.Physiol. Genomics 12: 97-112, 2003.Impact factor (2002): 4.667
128. Sull T.J., Chass G.A., Varró A., Papp J.Gy.: A comparative conformational analyisis of selected CNS stimulants.J. Mol. Structure (THEOCHEM) 623: 51-62, 2003.Imact factor (2002): 1.014
129. Takács J., Iost N., Lengyel Cs., Virág L., Nestic T.M., Varró A., Papp J.Gy. Multiple amiodarone like cellular electrophysiological effects of azimilide in canine cardiac preparations.Eur. J. Pharmacol. 470: 163-170, 2003. Impact factor (2002): 2.342
130. Zicha S., Moss I., Varró A., Papp J.Gy., Dumaine R., Antzelevitch C., Nattel S.Molecular basis of species-specific expression of repolarizing potassium currents in the heart.Am. J. Physiol. 285: H1641-H1649, 2003.Impact factor (2002): 3.369
131. Setiadi D.H., Chass G.A., Torday L.L., Varró A., Papp J.Gy.Vitamin E models. Shortened sidechain models of , , and tocopherol and tocotrienol - a dinsity function study. J. Mol. Structure (THEOCHEM) 637: 11-26, 2003.Impact factor (2002): 1.014
132. Mátyus P., Varga I., Rettegi T., Simay A., Kállay N., Károlyházy L., Varró A., Papp J.Gy.Novel antiarrhythmic compounds with combinated class IB and class III mode of action.Curr. Med. Chem. 11: 61-69, 2004.Impact factor (2002): 4.966
14
133. Varró A., Biliczki P., Iost N., Virág L., Hála O., Mátyus P., Papp J.Gy.Theoretical possibilities for the development of novel antiarrhythmic drugs.Curr. Med. Chem. 11: 1-11, 2004.Impact factor (2002): 4.966
134. Magyar J., Szentandrássy N., Bányász T., Fülöp L., Varró A., Nánási P.P.Effects of terpenoid phenol derivatives on calcium current in canine and human ventricular cardiomyocytes.Eur. J. Pharmacol. 487: 29-36, 2004.Impact factor (2002): 2.342
135. Fülöp L., Bányász T., Magyar J., Szentandrássy N., Varró A., Nánási P.P.Reopening of L-type calcium channel during the epicardial action potential in human ventricular myocytes.Acta Physiol. Scand. elfogadvaImpact factor (2002): 1.950
136. Iost N., Virág L., Hála O., Varró A., Thormāhlen D., Papp J.Gy. Effects of new anti-ischaemic drug, tedisamil on the transmembrane potassium currents in mamalian ventricular myocytes.Curr. Med. Chem. elfogadva Impact factor (2002): 4.966
137. Lau S.K., Chass G.A., Varró A., Papp J.Gy.: An exploratory ab initio conformational analyisis of selected fragments of nicotinamide adenine dinucleotide (NAD+). J. Mol. Structure (THEOCHEM) elfogadvaImpact factor (2002): 1.014
138. Sahai M.A., Chass G.A., Lovas S., Varró A., Papp J.Gy.: A modular numbering system of selected oligopeptides for molecular computations.J. Mol. Structure (THEOCHEM) elfogadvaImpact factor (2002): 1.014
139. Setiadi D.H., Chass G.A., Torday L.L., Varró A., Papp J.Gy.Vitamin E models. Oxidative ring opening of short sidechain model of -tocopherol and its thio- and seleno-congeners. A reaction mechanism with a closed electronic shell.J. Mol. Structure (THEOCHEM) in pressImpact factor (2002): 1.014
140. Varró A., Nánási P.P., Acsai K., Virág L., Papp J.Gy.Cardiac sarcolemmal ion channels and transporters as possible targets for antiarrhythmic and positive inotropic drugs: strategies of the past-perspectives of the future.Curr. Pharmaceut. Design in pressImpact factor (2002): 4.692
141. Lengyel Cs., Horváth Cs. Biliczki P., Dézsi L., Németh M., Iost N., Virág L., Tálosi L., Papp J.Gy., Varró A. Effect of a neuroprotective drug, eliprodil on cardiac repolarization: importance of the decreased repolarisation reserve in the development of proarrhythmic risk.Br. J. Pharmacol. elfogadva
15
Impact factor (2002): 3.450
142. Wettwer E., Hála O., Christ T., Heubach J.F., Dobrev D., Knaut M., Varró A., Ravens U.Role of IKur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation.Circulation elfogadvaImpact factor (2002): 10.255
143. Hőhn J., Pataricza J., Tóth G.K., Balogh Á., Varró A., Papp J.Gy. Levosimendan relaxes human saphenous vein by activation of potassium channels.Pharmacol. Toxicol. in pressImpact factor (2002): 1.271
Adott évi impact factor (1-143) összesen: 254.247 (2004.május 6.)
144. Iost N., Virág L., Varró A., Papp J.Gy. Comparison of Class I/A antiarrhythmic drugs, disopyramide, quinidine and procainamide on transmembrane potassium currents in rabbit ventricular myocytesJ. Cardiovasc. Pharmacol. & Ther. submitted
145. Iost N., Virág L., Varró A., Opincariu M., Takács J., Lengyel Cs., Bogáts G., Lathrop D.A., Papp J.Gy. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.J. Physiol. (London) submitted
2. Folyóiratban megjelent előadáskivonatok
1. Elharrar V., Nakaya Y., Varró A., Surawicz B.: Recovery of Vmax and of action potential duration in canine cardiac Purkinje fibers.FASEB J. 43: 419, 1984.
2. Kürthy M.K., Varró A., Rabloczky G., Mader M.J., Zubovics Z., Toldy L.: Pharmacological study of the new antiarrhythmic drug GYKI-23 107.Acta Physiol. Hung. 63: 250, 1984.
3. Varró A., Elharrar V., Surawicz B.: Effect of antiarrhythmic drugs on the range of premature action potential durations in cardiac Purkinje fibers.J. Am. Coll. Cardiol. 3: 617, 1984.
4. Bódi I., Varró A., Schmidt G., Rabloczky G.: Antiarrhythmic effects of amiodarone and its metabolite desethylamiodarone in conscious rats.J. Mol. Cell. Cardiol. 19. Suppl. 3: S7, 1987.
5. Jednakovits A., Bodi I., Varró A., Rabloczky G.: Frequency-dependent effects of antiarrhythmic drugs on the excitability and conduconduction time in rabbit right ventricular muscle.J. Mol. Cell. Cardiol. 19. Suppl. 3: S39, 1987.
16
6. Rablóczky G., Kürthy M., Heltai K., Mader M., Kasztreiner E., Varró A., Korosy J., Matyus P.: Comparative evaluation of cardiac actions of some new positive inotropic compounds with different modes of action.J. Mol. Cell. Cardiol. 19. Suppl. 3: S77, 1987.
7. Varró A., Surawicz B.: Effect of class II, III, IV antiarrhythmic drugs on the premature action potential duration (APD) in cardiac Purkinje and ventricular muscle.J. Mol. Cell. Cardiol. 19. Suppl. 3: S102, 1987.
8. Rabloczky G., Varró A., Kürthy M., Bodi I., Jednakovits A., Szathmary J.L., Jaszlitisz L., Király I. Pharmacology of B-GYKI-38 233, new antiarrhythmic agent.Pharmacol. Res. Comm. 20. Suppl. 1: 71, 1988.
9. Varró A., Nanasi P.P., Lathrop D.A.: Voltage clamp characterization of two normal populations of rabbit ventricular myocytes.Clin. Res. 37: 891(A), 1989.
10. Lathrop D.A., Varró A.: Modulation of the effects of sotalol on Purkinje stand electromechanical characteristics.FASEB J. 3: A1204, 1989.
11. Varró A., Lathrop D.A., Schwartz A.: Comparison of the rate-dependent effects of sotalol and of OPC-8212, a new positive inotropic compound that lengthens cardiac action potential duration.FASEB J. 3: A880, 1989.
12. Nanasi P.P., Danko M., Varró A., Lathrop D.A.: Nonlinear relationship between Vmax and h during repetive electrical activity of skeletal muscle.Biophys. J. 57: 105a, 1990.
13. Varró A., Nanasi P.P., Lathrop D.A.: Voltage clamp characterization of rabbit cardiac ventricular cyocytes.Biophys. J. 57: 134a, 1990.
14. Nanasi P.P., Knilans T.K., Varró A., Richards I.S., Lathrop D.A.: Biophasic effect of tetraethylammonium on canine Purkinje fiber action potential configuration.J. Mol. Cell. Cardiol. 22. Suppl.1: S3, 1990.
15. Knilans T.K., Varró A., Nanasi P.P., Lathrop D.A.: electrophysiological effects of FPL 13210 on canine Purkinje fiber action potential and Vmax.J. Mol. Cell. Cardiol. 22. Suppl.1: S16, 1990.
16. Varró A., Lathrop D.A.: Sotalol and mexiletine: A combination of rate-dependent electrophysiological effects.J. Mol. Cell. Cardiol. 22. Suppl.1: S16, 1990.
17. Jednakovits A., Bodi I., Kovacs A., Jaszlits L., Szilagyi G., Borzo E., Varró A., Rabloczky G.: Study of GYKI-46.544, a new bradycardiac calcium antagonist in isolated cardiovascular preparations.Eur. J. Pharmacol. 183: 1321, 1990.
17
18. Varró A., Nanasi P.P., Lathrop D.A.: Effect of sotalol on transmembrane ionic currents responsible for repolarization in cardiac ventricular myocytes from rabbit and guinea pig.J. Mol. Cel. Cardiol. 23. Suppl.5: S10, 1991.
19. Nanasi P.P., Varró A., Bryant S.H., Lathrop D.A.: Veratrine modified sodium channels in heart and skeletal muscle.Biophys. J. 59: 72a, 1991.
20. Lathrop D.A., Nanasi P.P., Varró A., Schwartz A.: Ionic basis for OPC-8212 (ARKIN-Z) induced increase action potential duration in isolated rabbit, guinea pig and human ventricular myocytes.J. Mol. Cell. Cardiol. 24. Suppl.1: S107, 1991.
21. Varró A., Eisner D.A.: Estimates of INaCa during ICa in rat ventricular myocytes.J. Mol. Cell. Cardiol. 24.Suppl.4: S42, 1991.
22. Nanasi P.P., Varró A., Lathrop D.A.: Ionic currents in isolated human cardiomyocytes.Muscle Res. Cell. Mot. 13: 248, 1992.
23. Varró A., Hester S.B., Eisner D.A.: An estimate of the relative contributions of the sarcoplasmic reticulum and calcium current to contraction of isolated rat ventricular myocytes.J. Physiol. 452: 127P, 1992.
24. Varró A., Lathrop D.A., Hester S.B., Nanasi P.P., Papp J.Gy.: A comparison of ionic currents and action potentials in rabbit, rat and guinea pig myocytes.J. Mol. Cell. Cardiol. 25. Suppl.1: S70, 1993.
25. Nagy A., Varró A., Papp J.Gy.: Effect of benzodiazepines on SA-nodal, AV-junctional and ventricular pacemaker activity of rabbit heart preparations.J. Mol. Cell. Cardiol. 25. Suppl.1.: S78, 1993.
26. Németh M., Varró A., Virág L., Hála O., Kovács G., Papp J.Gy.: The electrophysiological effects of tedisamil in human atrial and ventricular fibers.J. Mol. Cell. Cardiol. 26: LXXXV 335, 1994.
27. Leprán I., Baczkó I., Varró A., Papp J.Gy.: Effect of glibenclamide on ischaemia and reperfusion induced arrhythmias in rats.J. Mol. Cell. Cardiol. 26: LXXXIV 332, 1994.
28. Marton A., Hála O., Varró A., Papp J.Gy.: Analysis of the effects of EMD53998 and milrinone in slow response experiments.J. Mol. Cell. Cardiol. 26: LXXXIV 333, 1994.
29. Hála O., Marton A., Varró A., Papp J.Gy.: Effect of levosimendan and milrinone on slow response and delayed after depolarization.J. Mol. Cell. Cardiol. 26: LXXXIII 328, 1994.
30. Virág L., Varró A., Papp J.Gy.: Disopyramide decreases the transient outward current in rabbit isolated cardiac myocytes.J. Mol. Cell. Cardiol. 26: LXXXVII 345, 1994.
18
31. Varró A., Németh M., Hála O., Papp J.Gy.: The electrophysiological effects of tedisamil in dog cardiac Purkinje and ventricular muscle fibers.J. Mol. Cell. Cardiol. 26: LXXXVI 342, 1994.
32. Baczkó I., Leprán I., Varró A., Papp J.Gy.: Influence of pinacidil on reperfusion induced arrhythmias and sudden death in anesthetized rats.J. Mol. Cell. Cardiol. 26: LXXXII 325, 1994.
33. Negretti N., Varró A., Eisner D.A.: An estimate of net Ca loss from the cell during a single beat in rat ventricular myocytes.J. Physiol. 475P: 78P, 1994.
34. Lathrop D.A., , Nánási P.P., Bódi i., Takyi E., Pankucsi C.: Differences in the effects of d- and dl-sotalol on isolated human ventricular muscle electromechanical activity after ß-adrenoceptor stimulation.FASEB J. 9: A602, 1995.
35. Varró A., Virág L., Papp J.Gy.: The effects of acute and chronic amiodarone treatment on the cardiac calcium and potassium channels.Cardiol. Hung. 24.Suppl.1: 45, 1995
36. Baláti B., Varró A., Papp J.Gy.: Comparison of the electrophysiological effects of cibenzoline almokalant and amiodarone on isolated dog ventricular muscle.Cardiol. Hung. 24.Suppl.1: 36, 1995.
37. Fazekas T., Carlsson L., Scherlag B.J., Palmer M., Patterson E., Varró A., Papp J.Gy., Lazzara R.: Electrophysiological characterization of a novel Class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. Cardiol. Hung. 24.Suppl.3: 9, 1995.
38. Virág L., Varró A., Papp J.Gy.: Acute effect of amiodarone on ionic currents recorded from isolated rabbit ventricular myocytes.Cardiol. Hung. 24.Suppl.3: 44, 1995.
39. Hála O., Varró A., Papp J.Gy.: Bertosamil blocks the cardiac fast sodium channels with a mexiletine-like onset kinetics. Cardiol. Hung. 24.Suppl.3: 9, 1995.
40. Nánási P.P., Szigligeti P., Varró A., Pankucsi Cs.: Force-frequency relationship in mammalian cardiac muscles.J. Mol. Cell. Cardiol. 27: A126, 1995.
41. Németh M., Varró A., Papp J.Gy.: Tedisamil is more potent to inhibit IK(ATP) than glibenclamide in cardiac muscle.J. Mol. Cell. Cardiol. 27: A140, 1995.
42. Varró A., Virág L., Papp J.Gy.: The effects of chronic amiodarone treatment on the cardiac calcium and potassium channels. J. Mol. Cell. Cardiol. 27: A140, 1995.
43. Virág L., Varró A., Papp J.Gy.: Effect of disopyramide on potassium currents in isolated rabbit cardiac myocytes.
19
J. Mol. Cell. Cardiol. 27: A141, 1995.
44. Baczkó I., Leprán I., Varró A., Papp J.Gy.: Both opening and closing of ATP-sensitive potassium channels protect against lethal reperfusion arrhythmias in anaesthetized rats.J. Mol. Cell. Cardiol. 27: A143, 1995.
45. Fazekas T., Carlsson L., Scherlag B.J., Lengyel Cs., Varró A., Papp J.Gy., Lazzara R.: Proarrhythmic effect of GLG-V-13 in a rabbit model of the acquired long QT syndrome.J. Mol. Cell. Cardiol. 27: A197, 1995.
46. Fazekas T., Carlsson L., Scherlag B.J., Palmer M., Patterson E., Varró A., Papp J.Gy., Lazzara R.:Electrophysiological characterization of a novel K+-channel blocking antiarrhythmic agent, GLG-V-13, in the mammalian heart.Eur. Heart J. 16.Suppl: 405, 1995.
47. Varró A., Papp J.Gy., Németh M., Krassói I., Mester L., Hála O.: Direct and long-term electrophysiological effects of amiodarone in dog cardiac Purkinje and ventricular muscle fibres.Br. J. Pharmacol. 117: 226P, 1996.
48. Virág L., Iost N., Varró A., Papp J.Gy.: Comparison of several antiarrhythmic drugs on potassium currents in rabbit ventricular myocytes.J. Mol. Cell. Cardiol. 28: A58, 1996.
49. Baláti B., Noori S., Varró A., Papp J.Gy.: The cellular electrophysiological effects of desethylamiodarone in dog cardiac ventricular muscle and Purkinje fibers.J. Mol. Cell. Cardiol. 28: A60, 1996.
50. Baláti B., Noori S., Varró A., Papp J.Gy.A desethylamiodaron elektrofiziológiai hatásainak vizsgálata izolált kutyaszív preparátumokon.Cardiol. Hung. 25. Kongresszusi Előadáskivonatok: 52, 1996.
51. Iost N., Virág L., Varró A., Papp J.Gy.: The effects of procainamide on the cardiac potassium currents in rabbit ventricular myocytes.J. Mol. Cell. Cardiol. 28: A61, 1996.
52. Iost N., Virág L., Varró A., Papp J.Gy.A prokainamid hatásának vizsgálata a szív kálium áramaira nyúlszívbõl izolált kamraizom sejteken.Cardiol. Hung. 25. Kongresszusi Előadáskivonatok: 56, 1996.
53. Németh M., Varró A., Papp J.Gy.: Effect of antiarrhythmic drugs on the ATP-sensitive potassium current in dog ventricular myocardium.J. Mol. Cell. Cardiol. 28: A61, 1996.
54. Németh M., Virág L., Varró A., Papp J.Gy.: Comparison of the effects of restacorin and flecainide on various transmembrane potassium currents.Acta Physiol. Hung. 84: 317-318, 1996.
55. Krassói I., Varró A., Papp J.Gy.: Effect of restacorin on the early and delayed afterdepolarization in dog Purkinje fibres.Acta Physiol. Hung. 84: 299-300, 1996.
20
56. Virág L., Iost N., Varró A., Papp J.Gy.Antiaritmiás szerek hatása a szív kálium áramaira nyúlszívbõl izolált kamrai szívizomsejtekben.Cardiol. Hung. 25. Kongresszusi Előadáskivonatok: 68, 1996.
57. Baláti B., Varró A., Papp J.Gy.: Comparison of the cellular electrophysiological characteristics of canine left ventricular epicardium, midmyocardium and endocardium.Cardiol. Hung. 26. Suppl. 3: 24, 1997.
58. Iost N., Virág L., Varró A., Opincariu M., Szécsi J., Papp J.Gy.: Potassium currents in ventricular myocytes isolated from healthy human heart.Cardiol. Hung. 26. Suppl. 3: 25, 1997.
59. Opincariu M., Varró A., Hála O., Szécsi J., Papp J.Gy.: Frequency-dependent cellular electrophysiological effect of sotalol in healthy human ventricular muscle.Cardiol. Hung. 26. Suppl. 3: 88, 1997.
60. Opincariu M., Varró A., Hála O., Szécsi J., Papp J.Gy.: Frequency-dependent cellular electrophysiological effect of sotalol in undiseased human ventricular muscle.J. Kardiol. 4. Suppl. 2: 95, 1997.
61. Fazekas T., Krassói I., Lengyel Cs., Varró A., Papp J.Gy.: Suppression of erhythromycin-induced early afterdepolarizations and torsades de pointes ventricular tachycardia by mexiletine.PACE 20: 1479, 1997.
62. Virág L., Varró A., Fazekas T., Papp J.Gy.: Effect of a new class III antiarrhythmic drug. GLG-V-13, on various cardiac potassium currents in rabbit ventricular myocytes.Cardiol. Hung. 26. Suppl. 3: 90, 1997.
63. Katona T., Fazekas T., Krassói I., Varró A., Papp J.Gy.: Suppression of erythromycin-induced early afterdepolarizations and torsades de pointes ventricular tachycardia by mexiletine.Eur. Heart J. 18. Abs. Suppl: 569, 1997.
64. Fazekas T., Virág L., Varró A., Papp J.Gy., Berlin K.D., Scherlag B.J., Lazzara R.: Effects of GLG-V-13, a novel class III antiarrhythmic agent, on cardiac K+ currents in rabbit ventricular myocytes.J. Mol. Cell. Cardiol. 29: A118, 1997.
65. Németh M. Varró A., Papp J.Gy.: Effect of potassium channel blocking drugs the ATP-sensitive potassium current in dog ventricular myocardium.J. Mol. Cell. Cardiol. 29: A124, 1997.
66. Baláti B., Varró A., Papp J.Gy.: Comparison of the electrophysiological characteristics of canine left ventricular epicardium, midmyocardium and endocardium.J. Mol. Cell. Cardiol. 29: A122, 1997.
67. Virág L., Iost N., Fazekas T., Varró A., Scherlag B.J., Lazzara R., Papp J.Gy.: Modulation of various cardiac potassium currents by a new class III antiarrhythmic drug, GLG-V-13, in rabbit ventricular myocytes.Naunyn Schmiedeberg's Arch. Pharmacol. 356. Suppl. 1: R7, 1997.
21
68. Iost N., Virág L., Varró A., Papp J.Gy.: Comparison of the effects of class I/A antiarrhytmic drugs on potassium currents in rabbit ventricular myocytes.Naunyn Schmiedeberg's Arch. Pharmacol. 356. Suppl. 1: R8, 1997.
69. Baczkó I., Varró A., Mátyus P., Leprán I., Papp J.Gy.: Effect of D-Sotalol and GYKI-16638 on reperfusion induced arrhythmias in anaesthetized rabbits.J. Mol.Cell. Cardiol. 30: A4, 1998.
70. Iost N., Magyar J., Virág L., Bányász T., Varró A., Mohácsi A., Nánási P.P., Opincariu M., Szécsi J., Papp J.Gy.: Effect of endothelin on electrophysiological properties of human and canine ventricular myocytes.J. Mol.Cell. Cardiol 30: A69, 1998.
71. Baláti B., Simon J., Varró A., Papp J.Gy.: Cellular electrophysiological effects of chromanol 293B in canine cardiac ventricular muscle.J. Mol.Cell. Cardiol. 30: A133, 1998.
72. Iost N., Virág L., Opincariu M., Szécsi J., Varró A., Papp J.Gy.: Delayed rectifier potassium current in undiseased human ventricular myocytes.J. Physiol. (London) 606P: 55P, 1998.
73. Virág L., Iost N., Varró A., Papp J.Gy.: Lack of effect of class I/A antiarrhythmic drugs on the inward rectifier potassium current.J. Am. Coll. Cardiol. 31: 26C, 1998.
74. Varró A., Opincariu M., Szécsi J., Papp J.Gy.: Frequency-dependent cellular electropysiological effects of sotalol in undiseases human ventricular muscle.J. Am. Coll. Cardiol. 31: 26C, 1998.
75. Varró A., Iost N., Virág L., Opincariu M., Szécsi J., Papp J.Gy.: Potassium currents in ventricular myocytes isolated from undiseased human hearts.J. Am. Coll. Cardiol. 31: 26C, 1998.
76. Nánási P.P., Szigligeti P., Bányász T., Magyar J., Szigeti P., Papp Z., Varró A.: Intracullar calcium and electrical restitution in mammalian cardiac cells.J. Am. Coll. Cardiol. 31: 2C, 1998.
77. Iost N., Virág L., Varró A., Opincariu M., Szécsi J., Papp J.Gy.: Delayed rectifier potassium currents in undiseased human ventricular muscle.Cardiol. Hung. 27. Suppl. 1: 19, 1998.
78. Baczkó I., Varró A., Mátyus P., Leprán I., Papp J.Gy.: Influence of d-sotalol and GYKI-16638 on the occurrence of reperfusion induced fibrillation in rabbits.Cardiol Hung. 27. Suppl. 1: 34, 1998.
79. Opincariu M., Varró A., Hála O., Tálosi L., Szécsi J., Papp J.Gy.: Combined frequency-dependent cellular electrophysiological effects of sotalol and mexiletine in undiseased human ventricular muscle.Cardiol. Hung. 27. Suppl. 1: 41, 1998.
80. Papp N., Ötvös K., Hála O., Varró A., Papp J.Gy.: Experimental demonstration of arrhythmic activity of mexiletine in ventricular terminal Purkinje fibres.
22
Cardiol. Hung. 27. Suppl. 1: 36, 1998.
81. Ötvös K., Papp N., Hála O., Varró A., Papp J.Gy.: Analysis of the use-dependent electrophysiological effects of tedisamil and bertosamil in Purkinje fibres and ventricular myocardium.Cardiol. Hung. 27. Suppl.1: 36, 1998.
82. Fazekas T., Virág L., Iost N., Liszkai G., Varró A., Papp J.Gy.Scherlag B.J., Lazzara R.,: Modulation of various cardiac potassium currents by a new class III antiarrhythmic drug, GLG-V-13. in rabbit ventricular myocytes.Archives des Maladies du Couer et des Vaisseaus 91. No Special III: 15-2, 1998,
83. Opincariu M., Varró A., Hála O., Tálosi L., Szécsi J., Papp J.Gy.: Combined frequency-dependent cellular electrophysiological effects of sotalol and mexiletine in undiseased human ventricular muscle.Eur. Heart J. 19. Abs. Suppl: 43, 1998.
84. Iost N., Opincariu M., Szécsi J., Varró A., Papp J.Gy. : Delayed rectifier potassium current in undiseased human ventricular myocytes.Eur. Heart J. 19. Abs. Suppl.: 111, 1998.
85. Hála O., Varró A., Mátyus P., Papp J.Gy.Micro-electrophysiological effects of GYKI-16638, an antiarrhythmic agent, in ventricular muscle and Purkinje fibers.Kardiologia 7. Suppl.: 12A, 1998.
86. Virág L., Iost N., Varró A., Papp J.Gy.: Lack of effect of several Class I/A antiarrhythmic drugs on the inward rectifier potassium current.J. Mol. Cell. Cardiol. 30: A134, 1998.
87. Varró A., Baláti B, Takács J, Iost N, Virág L, Tálosi L, Papp J.Gy.: Does IKs play an important role in the repolarization in normal canine and human ventricular muscle and Purkinje fibres ?J. Physiol. (London) 515P: 183P, 1999.
88. Iost N., Virág L., Opincariu M., Szécsi J., Varró A., Papp J.Gy. Fast and slow delayed rectifier potassium currents in undiseased human ventricular myocytes.PACE 22: 762, 1999.
89. Virág L., Iost N., Varró A., Takács J., Baláti B, Opincariu M., Szécsi J., Papp J.Gy.: Pharmacological modulation of the delayed rectifier potassium current in human ventricular myocytes.Fundam. Clin. Pharm. 13. Suppl. 1: 69s, 1999.
90. Virág L., Németh M., Iost N., Mátyus P., Varró A., Papp J.Gy.: Effect of GYKI-16638, a new antiarrhythmic drug, on the action potential parameters and on various transmembrane potassium currents in dog heart preparations.Fundam. Clin. Pharm. 13. Suppl. 1: 223s, 1999.
23
91. Baláti B, Takács J., Iost N., Virág L., Simon J., Varró A., Papp J.Gy.: The role of the slow component of the delayed rectifier potassium current in dog ventricular muscle and Purkinje fibre repolarization.Fundam. Clin. Pharm. 13. Suppl. 1: 226s, 1999.
92. Iost N., Virág L., Varró A., Thormählen D., Papp J.Gy.: Effect of a new antiischaemic drug, tedisamil on the rapid and slow component of the delayed rectifier potassium current in guinea pig ventricular myocytes.Fundam. Clin. Pharm. 13. Suppl. 1: 236s, 1999.
93. Hála O., Ötvös K., Papp N., Varró A., Papp J.Gy.:Effect of Amiodarone, esethylamiodarone and SR-33589 on the early afterdepolarizations in canine Purkinje fibers.Fundam. Clin. Pharm. 13. Suppl.1: 227s, 1999.
94. Mátyus P., Varga I., Varró A., Papp J.Gy. GYKI-16638, a novel compound with amiodarone-like electrophysiological properties.Fundam. Clin. Pharm. 13. Suppl.1: 74s, 1999.
95. Varró A., Papp J.Gy.: Pharmacological modulation of K+ channels for transient outward current.Fundam. Clin. Pharm. 13. Suppl.1: 98s, 1999.
96 Varró A., Németh M., Takács J., Hála O., Baláti B., Papp J.Gy. Comparison of cellular electrophysiological effects of amiodarone and dronedarone in canine ventricular muscle and Purkinje fibers.Fundam. Clin. Pharm. 13. Suppl.1: 72s, 1999.
97. Iost N., Virág L., Opincariu M., Szécsi J., Varró A., Papp J.Gy.: The rapid and slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes.Eur. Heart J. 20. Abs.Suppl.: 344, 1999.
98. Varró A., Baláti B, Iost N., Takács J., Virág L., Tálosi L., Lathrop D., Papp J.Gy.: The role of the slow component of the delayed rectifier potassium current in dog ventricular muscle and Purkinje fibre repolarization.Eur. Heart J. 20. Abs.Suppl.: 575, 1999.
99. Varró A., Iost N., Virág L., Opincariu M., Szécsi J., Papp J.Gy.: Does IKs play an important role in the repolarization in normal human ventricular muscle?Circulation 100: I-495, 1999.
100. Iost N., Lengyel Cs., Virág L., Varró A., Papp J.Gy.: Does IKs play an important role in rabbit cardiac repolarization ?PACE 23: 661, 2000.
101. Iost N., Lengyel Cs., Virág L., Varró A., Papp J.Gy.: The re-evaluation of the role of the IKs in rabbit cardiac repolarization.J. Physiol. (London) 526P: 78P, 2000.
102. Nánási. P.P., Magyar J., Bányász T., Iost N., Virág L., Varró A.: Effects of endothelin on potassium and calcium currents in isolated canine and human ventricular myocytes.J. Physiol. (London) 526P: 81P, 2000.
24
103. Virág L., Iost N., Lengyel Cs., Baláti B., Varró A., Papp J.Gy.: Effect of chromanol 293B on ventricular repolarisation and transmembrane ionic currents in dog heart preparations.J. Physiol. (London) 526P: 98P, 2000.
104. Varró A., Papp J.Gy.: The cellular cardiac electrophysiological effects of dronedarone a new amiodarone like antiarrhythmic agent.Cardiovasc. Drugs and Ther. 14: 206p, 200, 2000.
105. Takács J., Lengyel Cs., Iost N., Virág L., Varró A., Papp J.Gy.: Cellular electrophysiological effects of the IKr and IKS blocker azimilide in dog heart preparations.Fundamental & Clin. Pharmacol. 15/Suppl.1: 44, 7P198, 2001.
106. Varró A., Takács J., Baláti B., Németh M., Hála O., Papp J.Gy.: Long-term cardiac electrophysiological effect of desethylamiodarone in dog cardiac muscle.Eur. Heart J. 22 Abs.Suppl.: P415, 2001.
107. Varró A., Takács J., Baláti B., Németh M., Hála O., Papp J.Gy.: Long-term cardiac electrophysiological effect of desethylamiodarone in dog cardiac muscle.Fundamental & Clin. Pharmacol. 15/Suppl.1: 45, 7P201, 2001.
108. Andrássy G., Dunai A., Simon E., Pászthory E., Tahy A., Varró A.: A clarithromycin hatása a QT-időre.Magyar Belorv. Arch. 55.Suppl.2: 54-55, 2002.
109. Biliczki P., Virág L., Iost N., Papp J.Gy., Varró A.: A repolarizációban részt vevő különböző kálium csatornák kölcsönhatásának vizsgálata kutya kamrai izmon: a „repolarizációs tartalék” szerepe.Cardiol. Hung. 32.Suppl: 36p, 2002.
110. Biliczki P., Virág L., Iost N., Papp J.Gy., Varró A.: Interaction of different potassium channels in dog ventricular repolarization: role of the repolarization reserve.J. Mol. Cell. Cardiol. 34: A10, 2002.
111. Iost N., Virág L., Lengyel Cs., Pacher P., Kecskeméti V., Kocsis E., Koltai M.Zs., Papp J.Gy., Varró A. Az alloxannal indukált diabétesz elektrofiziológiai hatásainak vizsgálata nyúlszíven.Cardiol. Hung. 32.Suppl: 29p, 2002.
112. Iost N., Virág L., Pacher P., Kecskeméti V., Koltai M.Z., Kocsis E., Papp J.Gy., Varró A.: Potassium currents in alloxan induced diabetes in rabbit hearts.J. Mol. Cell. Cardiol. 34: A29, 2002.
113. Lengyel Cs., Horváth Cs., Biliczki P., Dézsi L., Németh M., Iost N., Virág L., Varró A., Papp J.Gy.: Effect of eliprodil on cardiac repolarization.J. Mol. Cell. Cardiol. 34: A38, 2002.
114. Lengyel Cs., Iost N., Virág L., Pacher P., Kecskeméti V., Kocsis E., Papp Gy., Varró A.: A cukorbetegség szívelektrofiziológia hatásainak vizsgálata alloxan-diabeteszes nyúlmodellen.Diabet. Hung. 10.Suppl.1.: 47-48, 2002
25
115. Lengyel Cs., Iost N., Virág L., Pacher P., Kecskeméti V., Koltai M.Zs., Kocsis E., Papp Gy., Varró A.: Analysis of the transmembrane potassium currents in alloxan induced diabetes in rabbit hearts.Diabetologia 45.Suppl.2.: A372, 2002.
116. Pataricza J., Végh Á., Varró A.: Koszorúér preparátumok vazoreaktivitásának vizsgálata a bal koszorúér R. descendensének rövid idejű okklúzió/reperfúzióját követően kutyaszívben.Cardiol. Hung. 32.Suppl: 99p, 2002.
117. Pataricza J., Végh Á., Varró A. Effect of hypoxia in non-ischaemic coronary arteries isolated from normal and ischaemic canine hearts.J. Mol. Cell. Cardiol. 34: A49, 2002.
118. Varró A., Biliczki P., Virág L., Iost N., Papp J.Gy.: Interaction of different potassium channels in dog ventriuclar repolarization: role of repolarization reserve.Acta Physiol. Hung. 89: 116, 2002.
119. Virág L., Iost N., Papp Gy., Varró A.: Kis koncentrációban alkalmazott bárium hatása a szív kálium áramaira kutya kamrai miocitákon.Cardiol. Hung. 32.Suppl: 29p, 2002.
120. Virág L., Iost N., Papp J.Gy., Varró A.: Effect of Ba2+ in low concentrations on various transmembrane potassium currents in dog ventricular myocytes.J. Mol. Cell. Cardiol. 34: A67, 2002.
121. Varró A.: Ioncsatorna "remodelling" és pitvarfibrilláció.Cardiol. Hung. 32: 107, 2002.
122. Bartha J., Tóth A., Édes I., Vaszily M., Varró A., Papp Z.: Calpain-I sensitive proteins of the human myocardium.Exp. Clin. Cardiol. 8: 34p, 4, 2003. 123. Barta J., Tóth A., Édes I., Vaszily M., Varró A., Papp Z.Calpain-I sensitive proteins of the human myocardiumEur. J. Heart Failure 2: 44p, 213, 2003.
124. Biliczki P., Virág L., Iost N., Biliczki A., Papp J.Gy., Varró A.: Terikalant elektrofiziológiai hatásának vizsgálata kutya szívizmon.Cardiol. Hung. 33 Suppl.2: A96, 2003.
125. Borbély A., Barta J., Édes I., Vaszily M., Virág L., Varró A., Papp Z.: Peroxinitrit által kiváltott funkcionális változások humán kamrai szívizomsejteken.Cardiol. Hung. 33 Suppl.2: A64, 2003.
126. Borbély A., Barta J., Édes I., Vaszily M., Virág L., Varró A.Peroxinitrite induced mechanical alterations of the actin-myosin interaction in isolated human myocardail cells.Eur. J. Heart Failure 2: 21p, 132, 2003.
26
127. Borbély A., Barta J., Édes I., Vaszily M., Virág L., Varró A., Papp Z.Peroxynitrite induced mechanical alterations of the actin-myosin interaction in isolated human myocardial cells.Exp. Clin. Cardiol. 8: 35p, 7, 2003.
128. Iost N., Virág L., Varró A., Thormählen D., Papp J.Gy.Effects of tedisamil on transmembrane currents in dog, rabbit and guinea pig ventricular myocytes. Naunyn-Sch. Arch. Pharmacol. 367.Suppl.1: R99, 2003.
129. Márton Z., Pataricza J., Krassói I., Varró A., Papp J.Gy.: Thiorpan potencírozza a C-típusú nátriuretikus peptid érrelaxációs hatását sertés szív izolált koszorúéren.Cardiol. Hung. 33 Suppl.2: A96, 2003.
130. Pataricza J., Márton Z., Lengyel Cs., Tóth M., Varró A.Kalcium aktiválta káliumion-csatornák koszorúértónust szabályozó szerepe kísérletes diabetesben.Cardiol. Hung. 33 Suppl.2: A97, 2003.
131. Pataricza J., Krassói I., Márton Z., Varró A., Papp J.Gy.Interaction of C-type natriuretic peptide and NEP-enzyme inhibitors in the tone of isolated porcine coronary artery.Eur. J. Heart Failure 2: 175p, 801, 2003.
132. Vajda Sz., Baczkó I., Leprán I., Varró A.Antiarrhythmic activity of azimilide on ischaemia-reperfusion induced arrhythmias in anaesthetized rat.Exp. Clin. Cardiol. 8: 51p, 59, 2003.
133. Varró A., Iost N., Virág L., Lengyel Cs., Pacher P., Kecskeméti V., Koltai M.Z., Kocsis E., Papp J.Gy.: Diabetes attenuates the repolarization reserve in rabbit heart.PACE 26: S136, 2003.
134. Varró A., Iost N., Lengyel Cs., Virág L., Pacher P., Kecskeméti V., Kocsis E., Papp J.Gy.: Analysis of the transmembrane potassium currents in alloxan induced diabetes in rabbit hearts.PACE 26 4.Part II: 1085, 2003.
135. Varró A., Lengyel Cs., Virág L., Magyar J., Kecskeméti V., Tóth M., Bíró T., Nánási P., Papp J.Gy.Diabetes attenuates the repolarization reserve in dog and rabbit hearts.Exp. Clin. Cardiol. 8: 52p, 61, 2003.
136. Virág L., Iost N., Lengyel Cs., Biliczki P., Papp J.Gy., Varró A.: Az inward, rectifier kálium áram kisebb szerepet játszik a kamrai repolarizációban humán szívben, mint kutyában.Cardiol. Hung. 33 Suppl.2: A18, 2003.
27
137. Hála O., Wettwer E., Dobrev D., Christ T., Heubach J., Varró A., Papp J.Gy., Ravens U.: Effect of the inhibition of the IKur on the action potential shape in isolated human right atrial preparations and computer simulatons.Int. J. Bioelectromagnetism 5: 265-266, 2003.
138. Varró A.Possible intracellular mechanisms to increase the contractile function of the myocardium.Zeitschrift Kardiol. (Germ. J. Cardiol.) 92.Suppl.2.: II/41, H219, 2003.
3. Könyvrészletek
1. Kürthy M., Rabloczy G., Varró A., Szatmary L.G., Jaszlits L., Wellmann J., Érczy I.: New antiarrhythmic agent with positive cardiac actions (GYKI-38233), in : Advances in pharmacological research and practice. Pharmacological protection of the myocardium, eds.: Szekeres L., Papp J.Gy., Tardos L., Rabloczky G. (Pergamon Press, Budapest, Hungary) 211-215, 1985.
2. Varró A., Nakaya Y., Elharrar V., Surawicz B.: Intracellular electrophysiological effects of amiodarone after acute and chronic application in guinea pig ventricular and dog Purkinje fibers, in.: Advances in pharmacological research and practice. Pharmacological protection of the myocardium, eds.: Szekeres L., Papp J.Gy., Tardos L., Rabloczky G. (Pergamon Press, Budapest, Hungary) 159-162, 1985.
3. Surawicz B., Kuo C-S., Varró A.: Role of dispersion of repolarization, Chapter 9. in: Advances in Cardiac Electrophysiology and Arrhythmias, eds.: Fisch C., and Surawicz B., Elsevier pp. 108-20, 1991.
4. Varró A., Surawicz B.: Effect of antiarrhythmic drugs on membrane channels, in: Advances in Cardiac Electrophysiology and Arrhythmias, eds.: Fisch C., and Surawicz B. 1991.
5. Varró A.: Antiaritmiás szerek. In: Humán farmakológia. Szerk.: Vizi Sz. Medicina 3 fejezet, 605-622, 1997.
6. Szigligeti P., Bányász T., Magyar J., Varró A., Nánási P.P.: Effect of chelation of cytosolic Ca2+ on action potential duration and electrical restitution in dog, rabbit and rat ventricular myocytes in XIII Word Congress of Cardiology Monduzzi Editor pp. 207-211, 1998.
7. Papp Gy., Varró A.: A szívritmuszavarok keletkezésének celluláris elektrofiziológiai alapjai (II. fejezet) in: Klinikai szívelektrofiziológia és aritmológia. szerk.: Fazekas T., Papp Gy., Tenczer J. Akadémiai Kiadó, 21-50, 1999.
8. Varró A., Fazekas T.: Az antiarrhythmiás gyógyszerek klinikai alkalmazásának farmakológiai alapjai (XX. fejezet) in: Klinikai szívelektrofiziológia és aritmológia. szerk.: Fazekas T., Papp Gy., Tenczer J. Akadémiai Kiadó, 488-515, 1999.
9. Fazekas T., Varró A.: A klinikai arrhythmiák farmakoterápiája. Antiarrhythmiás és proarrhythmiás gyógyszerhatások (XXI. fejezet) In: Klinikai szívelektrofiziológia és aritmológia szerk.: Fazekas T., Papp Gy., Tenczer J. Akadémiai Kiadó, 516-535, 1999.
28
10. Varró A.: Antiarrhythmiás szerek. In: Humán farmakológia. A racionális gyógyszerterápia alapjai. 2. átdolg. kiad. Szerk.: Vizi E. Sz. Medicina KK., Budapest, 2002., 542-565.
29
Dr.VARRÓ ANDRÁS TUDOMÁNYOS PUBLIKÁCIÓIRA TÖRTÉNT FÜGGETLEN HIVATKOZÁSOK JEGYZÉKE
(önidézetek és a társszerzők önidézetei nélkül 2004. április 27.-ig)Független hivatkozások száma: 958
FOLYÓIRATOKRA
1) Gen. Pharmacol. 14: 709-711, 1983.Citations :
1, Max B.: Trends Pharmacol. 6.: 105, 1985.2, Zicha J.: Hypertension 8.: 1096, 1986.
2) J. Cardiovasc. Pharmacol. 7: 482-492, 1985Citations :
1, Feld G.K.: Circulation 74: 197, 1986.2, Talajic M.: Circulation 74: 1156, 1986.3, Bajaj A.K.: Circulation 75: 1065, 1987.4, Brunstin L.A.: J. Thor Surg. 94: 904, 1987.5, Colatsky T.J.: J. Cardiovasc. Pharmacol. 9: 435, 1987.6, Damiano B.P.: J. Cardiovasc. Pharmacol. 10: 498, 1987.7, Nattel S.: J. Pharmacol. Exp. Ther. 241: 275, 1987.8, Nattel S.: J. Pharmacol. Exp. Ther. 241: 282, 1987.9, Berman N.D.: J. Electrocard. 20: 297, 1987.10, Dangman K.H.: J. Cardiovasc. Pharmacol.12: 78, 1988.11, Franz M.R.: Circulation 77: 1177, 1977, 1988.12, Michelso E. L.: Med. Clin. Na. 72: 275, 1988.13, Miyawaki N.: J. Cardiovasc. Pharmacol. 12: 65, 1988.14, Pallandi R.T.: Cardiovasc. Res. 22: 171, 1988.15, Zabela P.V.: Terapevt. Arch. 60:142, 1988.16, Brown B.S.: J. Pharmacol. Exp. Ther. 248: 552, 1989.17, Costardj. A.: J. Pharmacol. Exp. Ther. 251: 39, 1989.18. Dangman J. Cardiovasc. Pharmacol. 13 : 846, 1989.19, Flemming M.A.: Can. J. Phys. Pharmacol. 67: 710, 1989.20, Kromer H.K.: Clin. Pharmacol. 46: 584, 1989.21, Nakaya Y.: Am. Heart J. 118: 907, 1989.22, Nattel S.: Circ. Res. 65: 1485, 1989.23, Podczeck A.: Eur. Heart J. 10: 928, 1989.24, Przywara D.A.: Circ. Res. 65 :185, 1989.25, Ranger S.: Circulation 79: 1000, 1989.26, Campbell T. : Handbook Exp. Pharm. 89 : 137, 19 89.27, Anderson K. P. : Circulation 81: 1024, 1990.28, Antoni H.: Herz 15: 61,1990.29, Campbell T.J.: Clin. Exp. Pharmacol. 17: 135, 1990.30, Hasegawa J.: Br. J. Pharmacol. 99: 815, 1990.31, Langenfe H.: J. Cardiovasc. Pharmacol. 15: 338, 1990.
30
32, Nademane K.: Circulation 81: 790, 1990.33, Rosenhec. S.: Pace 13:1379, 1990.34, Wang Z.: Circulation 82: 274, 1990.35, Zhu J.Q.: Acta Pharmacol. Si. 11: 220, 1990.36, Gintant G.: Card. Electrophys. Chapt 9.3: 1013, Futura. Publ. Co.1990.37, Delphon E.: Br. J. Pharmacol. 103: 1411, 1991.38, Dise T.L.: J. Pharmacol. Exp. Ther. 259: 535, 1991.39, Krishnan S.C.: Circ. Res. 69: 277, 1991.40, Nattel S.: Drugs 41: 672, 1991.41, Patterson E.: J. Pharmacol. Exp. Ther. 259: 558, 1991.42, Shirayam T.: J. Pharmacol. Exp. Ther. 259: 889, 1991.43, Woosley R. L: Ann. Rev. Pharmacol. 31: 427, 1991.44, Donck L.V.: Am. J. Phys. 261: 1828, 1991.45, Montero M.: J. Cardiovasc. Pharmacol. 20: 304, 1992.46, Shimizn. W.: Eur. Heart J. 13: 261, 1992.47, Villemai C.: Circulation 85: 2255, 1992.48, Kidwell G. A.: Circulation 87: 118, 199349, Symanski J.D.: Drugs 46: 219, 199350, Haberman R.J.: Am. Heart J. 126: 1121, 199351, Krishnan S.C.: Circulation 87: 562, 199352, Hasegawa J.: J. Clin. Pharmacol. 33: 444, 199353, Strambabadiale M.: Am. Heart J. 128: 973, 199454, Bargheer K.: Eur. Heart J. 15: 1409, 199455, Todt H.: Eur. J. Pharmacol. 265: 43, 199456, Chiale P.A.: J. Am. Coll. Cardiol. 23: 724, 199457, Koller B.: J. Cardiovasc. Pharmacol. 24: 753, 199458, Goldberger J.: Am. J. Cardiol. 73: 43, 199459, Kniczl V.: Arzneimittel-Forsch.(Drug Res) 44: 7, 199460, Bursill J.A.: J. Cardiovasc. Pharmacol. 23: 833, 199461, Sakai R.: J. Cardiovasc. Pharmacol. 25.: 953, 1995.62, Stanton M.S.: Cardiac electrophysiology. From cell to bedside Chapter 112. pp. 1314 Saunders 199563, Sager P.T.: Am.J. Cardiol. 82: I20-I30, 199864, Kirchhof P.F.: Circulation 97: 2567, 199865, Sager P.T.: 82: 120, 199866, Mestre M.: Fund. Clin. Pharmacol. 14: 107, 2000.67, Helie F.: Can. J. Physiol. Pharmacol. 81: 413, 2003.
3) J. Pharmacol. Exp. Ther. 223: 304-311, 1985.Citations :
1, Arnsdorf M.F.: Circ. Res. 61: 244, 1987.2, Gyöngyösi M.: Orvosképzés 62: 29, 19873, Endersen K.: Eur. J. Pharmacol. 35 : 467, 1988.4, Salata J.J.: Circ. Res. 62: 324, 1988.5, Zabela P. V.: Terapevt Arch. 60: 142, 1988.6, Costard. A.: J. Pharmacol. Exp. Ther. 251: 39, 1989.7, Endresen K.: Clin. Pharmacol. 45: 387, 1989.
31
8, Freysz M.: Anaesthes. 70: 799, 1989.9, Harumi K.: Am. J. Cardiol. 64: 10, 1989.10, Saitoh H.: Circulation 80: 1421, 1989.11, Chiavo D.R.: Nature 343: 653, 1990.12, Endersen K.: Eur. J. Clin. Pharmacol. 39: 123, 1990.13, Kobayashi Y.: Circulation 86: 955, 1992.14, Yorikane R.: J. Cardiovasc. Pharmacol. 20: 955, 1992.15, Björnstad H.: Cardiovasc. Res. 27: 946, 1993.16, Chezalviel F.: J. Cardiovasc. Pharmacol. 21: 212, 1993.17, Wyse K.R.: J. Cardiovasc. Pharmacol. 21: 316, 1993.18, Liu Y.: Cardiovasc. Res. 27: 1991, 1993.19, Malfatto G.: Pace Pacing Clin. Electrophysiol. 17: 2074, 1994.20, Bjornstad H.: Cardiovasc. Res. 28: 55, 1994.21, Bjornstad H.: Acta Anaesth. Scand. 39: 659, 199522, Pankucsi C.: Naunyn-Sch. Arch. Pharmacol. 352: 520, 1995.23, Liu D.: J. Pharmacol. Exp. Ther. 276: 568, 1996.24, Taggart P.: Circulation 94: 2526, 1996.25, Qi A.Z.: Can. J. Physiol. Pharmacol. 75: 255, 1997.26, Padrini R.: Pharmacol. Res. 35: 409, 1997.27, Qu Z.L.: Am. J. Physiol. 45: H269, 1999.
4) Eur. J. Pharmacol.112: 419-422, 1985.Citations:
1, Fazekas T.: Orvosképzés 61: 112, 19862, Follmer C.H.: J. Pharmacol. Exp. Ther. 243: 187, 1987.3, Pallandi R.T.: Br. J. Pharmacol. 92: 97, 1987.4, Talajic M.: Circulation 75: 265, 1987.5, Fazekas T.: Magyar Belorv. Arch 41: 201, 19886, Aomine M.: Gen. Pharmacol. 19: 601, 1988.7, Aomine M.: Gen. Pharmacol. 19: 609, 1988.8, Aomine M.: Naunyn-Schmied. Arch. Pharmacol. 338: 589, 1988.9, Cascio W.E.: Am. J. Cardiol. 61: 1042, 1988.10, Franz M. R.: Circulation 77: 1177, 1988.11, Nattel S.: Drugs 36: 121, 1988.12, Pallandi R.T.: Cardiovasc. Res. 22: 171, 1988.13, Anderson K.P.: Circulation 79: 948, 1989.14, Delphon E.: Br. J. Pharmacol. 96: 970, 1989.15, Gallaghe. D.E.: J. Cardiovasc. Pharmacol. 13: 723, 1989.16, Biagetti M.O.: J. Cardiovasc. Pharmacol. 15: 918, 1990.17, Golovina V.A.: Kardiol. 30: 110, 1990.18, Quinteir R.A.: J. Cardiovasc. Pharmacol. 16: 931, 1990.19, Rosenhec S.: PACE 13: 1379, 1990.20, Tande P.M.: Pharmacol. Toxicol. 66: 18, 1990.21, Gwilt M.: J. Cardiovasc. Pharmacol. 17: 376, 1991.22, Honjo H.: Br. J. Pharmacol. 102: 651, 1991.23, Ranger S.: Circulation 83: 1987, 1991.24, Stark G.: Bas. Res. Cardiol. 86: 136, 1991.
32
25, Stark G.: Cardiovasc. Res. 25: 807, 1991.26, Chiamvim N.: Am. J. Cardiol. 70: 598, 1992.27, Kodama J.: Br. J. Pharmacol. 107: 502, 1992.28, Li J.Y.M.: Cardiovasc. Res. 26: 1116, 1992.29, Sagert P.T.: Circulation 88: 1063, 1993.30, Symanski J.D.: Drugs 46: 219, 1993.31, Nattel S.: Am. J. Cardiol. 72: F13, 1993.32, Katritsis D.: Clin. Cardiol. 17: 142, 1992.33, Nanas J.N.: Circ. 91.: 451, 1995.34, Sosunov E.A.: J. Pharmacol. Exp. Ther. 278: 906, 1996.35, Kodama I.: Cardiovasc. Res. 35: 13, 1997.36, Sicouri S.: J. Cardiovascular Electrophys. 8: 1269, 1997.37, Zhou L.: J.Am.Coll.Cardiol. 31: 1672, 1998.38, Nánási P.P.: Cardiovasc. Drug Review 15: 314, 1997.39, Kodama I.: Am. J. Cardiol.84: 20R, 1999.40, Moreau D.: Mol. Cell. Biochem. 194: 291, 1999.41, Kirchhof P.: J. Pharmacol. Exp. Ther. 305: 257, 2003.42, Lalevee N.: J. Cardiovasc. Electrophysiol. 14:885, 2003.43, Gautier P.: J. Cardiovasc. Pharmacol. 41: 191, 2003.
6) J. Cardiovasc. Pharmacol. 8: 178-185, 1986.Citations:
1, Colatsky T.J.: J. Cardiovasc. Pharmacol. 9: 435, 1987.2, Franz M.R.: Circulation 77: 1177, 1988.3, Wasserstrom J.A.: Am. J. Phys. 254: 1157, 1988.4, Costard. A.: J. Pharmacol. Exp. Ther. 251: 39, 1989.5, Davideko J.M.: Circulation 79 : 674, 1989.6, Gautier P.: J. Cardiovasc. Pharmacol. 13: 328, 1989.7, Funck-Brentano C.: Am. J. Cardiol. 66: 812, 1990.8, Mortensen E.: Cardiovasc. Res. 24: 911, 1990.9, Tande P.M.: J. Cardiovasc. Pharmacol. 16: 401, 1990.10, Wang Z.: Circulation 82: 274, 1990.11, Björnstad H.: Am. Heart J. 121: 1429, 1991.12, Nattel S.: Drugs 41: 672, 1991.13, Schmitt C.: Am. J. Cardiol. 68:1183, 1991.14, Vanhoutte P.F.: Arch. J. Pharmacol. 310: 102, 1991.15, Vanhoutte P.F.: Br. J. Pharmacol. 103: 1275, 1991.16, Follmer C.H.: Cardiovasc. Res. 26: 1121, 1992.17, Lee R.J.: J. Am. Coll. Cardiol.19: 614, 1992.18, Rasmussen H.S.: J. Cardiovasc. Pharmacol. 20: S96, 1992.19, Tamargo J.: Eur. Heart J.13: 2, 1992.20, Vanhoutte P.F.: Naunyn-Schmied. Arch. Pharmacol. 344: 662, 1991.21, Björnstad H.: Cardiovasc. Res. 27: 946, 1993.22, Funck-Brentano C.: Fun. Clin. Pharmacol. 7: 51, 1993.23, Shimizu A.: J. Cardiovasc. Pharmacol. 21: 656, 1993.24, Sager P.T.: Circulation 88: 1063, 199325, Haberman R.J.: Am. Heart J. 126: 1121, 1993.
33
26, Wang Z.G.: J. Pharmacol. Exp. Ther. 267: 575, 1993.27, Fitton A.: Drugs 46: 678, 1993.28, Funck-Brentano C.: Eur. Heart. J. 14: 30, 1993.29, Zaza A.: J. Pharmacol. Exp. Ther. 269: 336, 1994.30, Oliler A.: Naunyn-Schmied. Arch. Pharmacol. 349: 602, 1994.31, Rosmussen H.S.: Electropharmacological control of arrhythmias. 551, Chapter 37. Futura Co 1994.32, Follmer C.H.: Electropharmacological control of arrhythmias. 611, Chapter 42. Futura Co 1994.33, Chezalvielguilbert F.: J. Am. Coll. Cardiol. 26: 787, 199534, Hondeghem L.C.: Cardiac electrophysiology. From cell to bedside. Chapter 114. p. 1335 Saunders, 199535, Pankucsi C.: Naunyn-Sch. Arch. Pharmacol. 352: 520, 1995.36, Sager P.T.: J. Cardiovasc. Electrophysiol. 7: 102, 1996.37, Tuininga Y.S.: PACE-Pac. Clin. Electrophys. 19: 802, 1996.38, Sweeney R.J.: PACE-Pac. Clin. Electrophys. 19: 50, 1996. 39, Abrahamsson C.: J. Cardiovasc. Electrophysiol. 7: 1074, 1996.40, Bordier P.: Ann. Cardiol. Angeiol. 45: 263, 1996. 41, Priori S.G.: Circ. Res. 78: 1009, 1996.42, Xu S.Z.: Drug Develop. Res. 40: 94, 1997.44, Berul C.I.: Circulation 94: 2641, 1996.44, Bosch R.F.: Cardiovasc.Res. 38: 441, 1998.45, Han H.S.: Cardiovasc. Drug Ther. 11: 767, 1998.46, Picard S.: J.Cardiovasc. Pharm. 31: 126, 1998.47, Chuck: Circ. Res. 81: 470, 1997.48, Sosunov E.A.: Circulation 96: 4011, 1997.49, Sosunov E.A.: J. Pharm. Exp. Ther. 280: 146, 1999.50, Peralta A.O.: J. Am. Coll. Cardiol. 36: 1404, 2000.51, Saba S.:Trends Cardiovasc. Med. 10: 122, 2000.
7) J. Pharm. Pharmacol. 38: 772 -773, 1986.Citation:
1, Martonau P.A.: Eur. J. Pharmacol. 143: 391, 1987.
8) Kisérl. Orvostud. 38: 113-124, 1986.Citations:
1, Gyöngyösi M.: Orvosképzés 62: 29, 19872, Fazekas T.: Orvosképzés 64: 133, 1989
9) Kisérl. Orvostud. 38: 572-591, 1986.Citation:
1, Fazekas T.: Orvosképzés 64: 133, 1989
10) Kisérl. Orvostud. 38: 133-149, 1986Citation:
34
1, Fazekas T.: Orvosképzés 64: 133, 1989.
11) Eur. J. Med. Chem./Chim. Ther. 21: 370-378, 1986.Citations:
1, Alker D.: Tetrahedro. A.1: 877, 1990.2, Benalil A.: Tetrahedro 47: 8177, 1991.3, Cooper G.F.: Tetrahedro 33: 5895, 1992.4, Sibi M.P.: J. Org. Chem. 57: 4329, 1992.5, Laguerre M.: Eur. J. Med. Chem. 28: 77, 1993.6, Sibi M.P.: J. Org. Chem. 64: 6434, 19997, Lucet D.: Angewandle Chemic. Int. Ed. 37: 2581, 1998.8, Sohar P.: J. Chem. Soc. Perk T. 2: 287, 2000.9, Posakony J.J.: Synthesis-Stuttgart 6: 766, 2002.10, Posakony J.J.: Synthesis-Stuttgart 7: 859, 2002.11, Posakony J.J.: J. Org. Chem. 67: 5164, 2002.12, Melenedz R.E.: Tetrahedron 59: 2581, 2003.13, Williams A.J.: Org. Lett. 5: 811, 2003.
13) J. Pharm. Pharmacol.: 39: 483-84, 1987.Citations :
1, Tsuchuha K.: J. Cardiovasc. Pharmacol. 18: 445, 1991.2, Gill J.: Drugs 43: 69, 1992.
15) J. Cardiovasc. Pharmacol. 10: 407-414, 1987.Citations:
1, Meng H.: Can. J. Phys. Pharmacol. 68: 856, 1990.2, Funck-Brentano C.: Circulation 83: 536, 1991.3, Fantrez V.M.: J. Cardiovasc. Pharmacol. 19: 308, 1992.4, Kobayash Y.: Circulation 86: 955, 1992.5, Follmer C.H.: Electrophysiological control of arrhythmias. 611, Chapter 42. Futura Co 1994.6, Liu D.: J. Pharmacol. Exp. Ther. 276: 568, 1996.7, Zhang H.: Theor. Biol. 184: 119, 1997.8, Koller M.L.: Am. J. Physiol. 44: H1635, 1998.9, Riccio M.L.: Circ. Res. 84: 955,1999.10, Helie F.: Can. J. Physiol. Pharmacol. 81: 413, 2003.11, Cheng Y.N.: Am. J. Physiol. 286: H310, 2004.
17) J. Cardiovasc. Pharmacol. 11: 251-257, 1988.Citation:
35
1, Arrowsmije: Annual Rep. M. 25: 79, 1990
18) Eur. J. Pharmacol.154: 11-18, 1988.Citations:
1, Winslow E.: J. Cardiovasc. Pharmacol. 16: 896, 1990.2, Gill J.: Drugs 43: 69, 1992.3, Symanski J.D.: Drugs 46: 219, 19934, Hou Z.Y.: Eur. Heart J. 16: 521, 1995.5, Kodama I.: Cardiovasc. Res. 35: 13, 1997.6, Sicouri S.: J.Cardiovasc. Electrophys. 8: 1269, 1997.7, Watanabe Y.: Jpn. J. Pharmacol. 90: 21, 2002.
19) Arch. Int. Pharmacodyn. Ther. 292: 157-165, 1988.Citations :
1, Winslow E.: J. Cardiovasc. Pharmacol. 14: 205, 1989.2, Anderson K.P.: Circulation 81: 1024, 1990.3, Hill B.C.: J. Cardiovasc. Pharmacol. 16: 871, 1990.4, Duker B.G.D.: Cardiovasc. Res. 25: 217, 1991.
21) Eur. J. Pharmacol. 164: 487-496, 1989.Citations :
1, Bjőrnstad H.: Am. Heart J. 121: 1429, 1991.2, Feldman A.M.: Am. J. Cardiol. 68: 1203, 1991.3, Busch F.W.: Eur. J. Clin. Pharmacol. 42: 629, 1992.4, Feldman A.M.: N. Eng. J. Med. 326: 1565, 1992.5, Martin C.L.: J. Cardiol. Pharmacol. 19: 830, 1992.6, Reck G.: Pharmazie 47: 192, 1992.7, Fitton A.: Drugs 46: 678, 1993.8, Feldman A.M.: Cardiovasc. Drug Res. 11: 1, 1993.9, Feldman A.M.: N. Engl. J. Med. 329: 149, 1993.10, Shimizu A.: J. Cardiovasc. Pharmacol. 21: 656, 1993.11, Feldman A.M.: Cor. Art. Dis. 5: 107, 1994.12, Feldman A.M.: J. Am. Coll. Cardiol. 22: 1223, 1993.13, Ylimayry S.: Am. J. Cardiol. 78: 372, 1996.14, Chi J.F.: Br. J. Pharmacol. 118: 503, 1996.15, Yang T.: J. Pharmacol. Exp. Ther. 280: 1170, 1997.16, Editorial Material Current Problems in Cardiology 21: 527, 1996.17, Wandel C.: Clin. Pharmacol and Ther. 63: 506, 1998.18, Qu Z.L.: Am. J. Physiol. 45: H269, 1999.19, Yoshimura A.: Arzneimittel Forsch. 49: 420, 1999.
22) J. Cardiovasc. Pharmacol. 14: 681-687, 1989.Citations:
1, Docherty J.R.: Pharmacol. Rev. 42: 103, 1990.
36
2, Artman H.: Cardiovasc. Res. 26: 3, 1992.3, Berrebibertrand I.: FEBS Letters 348: 55, 1994.4, Surawicz B.: Electrophysiologic basic of ECG and cardiac arrhythmias 454,
Chapter 23 Williams and Wilkins Co 1995.
23) Can. J. Physiol. Pharmacol. 67: 1463-1467, 1989.Citations:
1, Fitton A.: Drugs 46: 678, 1993.2, Antonaccio M.J.: Electropharmacological control of arrhythmias. 465, Chapter 33. Futura Co 1994.3, Surawicz B.: Electrophysiologic basic of ECG and cardiac arrhythmias 454,
Chapter 23 Williams and Wilkins Co 1995.4, Hoverkamp W.: Cardiovasc. Drug Ther. 9.S2: 195, 1995.5, Advani S.V.: Drugs 49: 664, 1995.6, Wanless R.S.: Am. Heart J. 133: 441, 1997.
24) J. Cardiovasc. Pharmacol. 14: 908-919, 1989.Citation:
1, Follmer C.H.: Circulation 82: 289, 1990.
27) Br. J. Pharmacol. 99: 119-123, 1990.Citations:
1, Sauviat M.P.: Pflügers Arch. 418: 261, 1991.2, Evans J.M.: Ann. Rep. M. 26: 73, 1991.3, Longman S.D.: Med. Res. Rev. 12: 73, 1992.4, Bjőrnstad H.: Cardiovasc. Res. 27: 946, 1993.5, Legrand B.: Eur. J. Pharmacol. 229: 91, 1992.6, Funck-Brentano C.: Arch. Malad. Coer. Vais. 85: 9, 1992.7, Tao Y.: Cardiovasc. Res. 26: 1109, 1992.8, Atwal K.S.: Med. Res. Rev. 12: 569, 1992.9, Dalonzo A.J.: Cardiovasc. Res. 26: 1046, 1992.10, Xu Y.G.: Acta Pharmacol. Sinica 14: 186, 1993.11, Dalonzo A.J.: J. Cardiovasc. Pharmacol. 21: 677, 1993.12, Dalonzo A.J.: Cardiovasc. Res. 28: 881, 1994.13, Billman G.E.: Cardiovasc. Res. 28: 762, 1994.14, Wilde A.A.M.: Cardiovasc. Res. 28: 16, 1994.15, Atwal K.S.: Drug Develop. Res. 33: 250, 1994.16, Vegh A.: Eur. J. Pharmacol. 305: 163, 1996.17, Xu J.: Am. J. Physiol. 39: H1850, 1996.18, Hayashi H.: J. Cardiovasc. Pharmacol. 27: 816, 1996.19, Tosaki A.: J. Pharmacol. Exp. Ther. 282: 309, 1997.20, Carmeliet E.: Progress in Biophysics and Mol. Biol. 70: 1, 1998.21, Shimizu U.: Circulation 97: 1581, 1998.22, Brady P.A.: J.Am.Coll.Cardiol 31: 950, 1998.23, Kita H.: J. Cardiovasc. Pharmacol. 32: 791, 1998
37
24, Shimizu W.: Circulation 102: 706, 2000.25, Isobe N.: Circ. J. 66: 943, 2002.
28) Br. J. Pharmacol. 99: 124-130, 1990.Citations:
1, Fitton A.: Drugs 46: 678, 1993.2, Todt H.: Eur. J. Pharmacol. 265: 43, 1994.3, Antonaccio M.J.: Electropharmacological control of arrhythmias. 465, Chapter
33. Futura Co 1994.4, Chezalvielguilbert F.: J. Am. Coll. Cardiol. 26: 787, 1995.5, Hondeghem L.M.: Cardiac electrophysiology. From cell to bedside Chapter114. p. 1344 Saunders, 1995.6, Fazekas T.: Cardiologica Hungarica 24: 7, 19957, Chezalvielguilbert F.: J. Am. Coll. Cardiol. 26: 787, 1995.8, Priori S.G.: Circ. Res. 78: 1009, 1996.9, Pfammatter J.P.: Pediatr. Cardiol. 18: 28, 1997.10, Cirtz S.D.: J. Mol. Cell. Cardiol. 29: 1123, 1997.11, Weissenburger J.: Circulation 94: 2986, 1996.12, Qu Z.L.: Am. J. Physiol. 45: H269, 1999.13, Merot J.: J. Am. Coll. Cardiol. 36: 939, 2000.14, Walker M.L.: Cardiovasc. Res. 57: 599, 2003
29) J. Cardiovasc. Pharmacol. 16: 557-567, 1990.Citations:
1, Chezalviel F.: J. Cardiovasc. Pharmacol. 21: 212, 1993.2, Fitton A.: Drugs 46: 678, 19933, Todt H.: Eur. J. Pharmacol. 265: 43, 1994.4, Antonaccio M.J.: Electropharmacological control of arrhythmias. 465, Chapter 33. Futura Co 1994.5, Chezalvielguilbert F.: J. Am. Coll. Cardiol. 26: 787, 1995.6., Fazekas T.: Cardiol. Hung. 24: 7, 1995.7, Hallmann K.: Pharmacol. & Toxicol. 77: 250, 1995.8, Priori S.G.: Circ. Res. 78: 1009, 1996.9, Melnikov A.L.: Gen. Pharmacol. 27: 665, 1996.10, Győngyősi M.: Cardiologica Hungarica 25: 7, 1996.11, Weissenburger J.: Circulation 94: 2986, 1996.12, Sicouri S.: J.Cardiovasc. Electrophys. 8: 1280, 1997.13, Vaughan Williams E.M.: Control of cardiac rhthm Lippincott-Raven 107p, Chapter 9, 1998.14, Kovács A.: J. Cardiovasc. Pharmacol. 37: 78, 2001.15, Walker M.L.: Cardiovasc. Pharmacol. 57: 599, 2003.16, Mortl D.: J. Cardiovasc. Pharmacol. 41: 870, 2003.
30) Gen. Pharmacol. 21: 747-51, 1990.Citation:
38
1, Devlin C.L.: J. Exp. Biol. 179: 63, 1993.2, Devlin C.L.: Comp. Biochem. Physiol. 116: 93, 1997.3, Secilmis A.: Acta Medica Okayama 51: 115, 1997.4, Devlin C.L.:Biol. Bull. 200: 344, 2001.
31) J. Cardiovasc. Pharmacol. 16: 757-63, 1990.Citation:1, Hondeghem L.M.: J. Cardiovasc. Electrophysiol. 14: 287, 2003.
2, Pak H.N.: Circulation 108: 3149, 2003.
32) Naunyn-Schmiedeberg's Arch. Pharmacol. 342: 691-697, 1990.Citation:
1, Tuininga Y.S.: Int. J. Clin. Pharmacol. Ther. 32: 278, 1994.
34) Br. J. Pharmacol.103: 1568-1572, 1991.Citations:
1, Atwal K.S.: Med. Res. Rev. 12: 569, 1992.2, Black S.C.: Cardiovasc. Drug Res. 10: 170, 1992.3, Gout B.: J. Pharmacol. Exp. Ther. 262: 987, 1992.4, Mortensen E.: J. Cardiovasc. Pharmacol. 19: 216, 1992.5, Rasmussen H.S.: J. Cardiovasc. Pharmacol. 20: S96, 1992.6, Tao Y.: Cardiovasc. Res. 26: 1109, 1992.7, Yang T.: Cardiovasc. Drug 6: 429, 1992.8, Yang T.: J. Cariovasc. Pharmacol. 20: 889, 1992.9, Funck-Brentano C.: Fund. Clin. Pharmacol. 70: 51, 1993.10, Yang T.: Circ. Res. 75: 870, 1994.11, Yuan S.: Eur. Heart J. 15: 514, 1994.12, Baskin E.P.: J. Cardiovasc. Pharmacol. 24: 199, 1994.13, Rasmussen H.S.: Electropharmacological control of arrhythmias. 551, Chapter 37. Futura Co 1994.14, Lecoz F.: Clin. Pharmacol. Ther. 57.: 533, 1995.15, Bril A.: J. Pharmacol. Exp. Ther. 273.: 1264, 1995.16, Faivre J.F.: Cardiovasc. Drug Rev. 13: 33, 1995.17, Grover G.J.: J. Cardiovasc. Pharmacol. 26: 145, 1995.18, Legard B.: J. Cardiovasc. Pharmacol. 26.: 803, 1995.19, Rees S.: Pharmacol. Ther. 69: 199, 1996.20, Sager P.: J. Cardiovasc. Electrophysiol. 7: 102, 1996.21, Martin C.L.: J. Pharmacol. Exp. Ther. 278: 154, 1996.22, Cha Y.M.: J. Cardiovasc. Electrophysiol. 7: 809, 1996.23, Sosunov E.A.: J. Pharmacol. Exp. Ther. 278: 906, 1996.24, Anyukhovsky E.P.: J. Pharmacol. Exp. Ther. 280: 1137, 1997.25, Demolis J.L.: Circulation 94: 1592, 1996.26, Chen J.G.: J. Cardiovasc. Pharmacol. 28: 576, 1996.
39
27, Camm A.J.: Clinical. Cardiol. 20: 704, 1997.28, Bril A.: Cardiovasc. Res. 137: 130, 1998.29, Gjini V.: J.Cardiovasc. Pharmacol. 31: 95, 1998.30, Kobayashy Y.: J.Cardiovasc. Pharmacol. 30: 367, 1997.31, Doggrell S.A.: Current Research in Ion Channel Modulators 3: 77, 1998.32, Lande G.: Clin. Pharm. Ther. 64: 312, 1998.33, Bosch R.F.: Cardiovasc. Res. 38: 441, 1998.34, McClellan K.J.: Drugs 58: 1043, 1999.35, Satoh Y.: Jpn. J. Pharmacol. 81: 79, 1999.36, Dumotier B.M.: Drug Dev. Res. 47: 63, 1999. 37, Kalus J.S.: Ann. Pharmacother. 34: 44, 2000.38, Torp-Pedersen C.: Expert. Opin. Inv. Drug 9: 2695, 2000. 39, Falk R.H.: Am. Heart J. 140: 697, 2000. 40, Tendera M.: Am. Heart J. 142: 93, 2001 .41, Kovacs A.: J. Cardiovasc. Pharmacol. 37: 78, 2001. 42, Doggrell S.A.: J. Pharm. Pharmacol. 54: 707, 2002.43, Lei M.: Cardiovasc. Res. 53: 68, 2002.44, Allen M.J.: Br. J. Clin. Cardiol. Pharmacol. 53: 59, 200245, Liu H.: J. Med. Chem. 45: 2953, 2002.46, Elming H.: Expert. Opin. Pharmacol. 4: 973, 2003.
35) Life Sci. 48: Pl 7-Pl 12, 1991.Citations:
1, Wettwer E.: Cardiovasc. Res. 26: 1145, 1992.2, Yang T.: J. Cardiovasc. Pharmacol. 20: 889, 1992.3, Fitton A.: Drugs 46: 678, 1993.4, Mortensen E.: Cardiovasc. Drug Rev. 11: 370, 1993.5, Corr P.B.: Electropharmacological control of arrhythmias. 279, Chapter 21. Futura Co 1994.6, Antonaccio M.J.: Electropharmacological control of arrhythmias. 279, Chapter 21. Futura Co 1994.7, Volk K.A.: Am. J. Physiol. - Ren. Fluid Electrol. Physiol. 36: 671, 1994.8, January C.T.: Cardiac electrophysiology. From cell to bedside. Chapter 27. p. 276 Saunders 1995.9, Advani C.: Drugs 49.: 664, 1995.10, Gibb V.J.: Mathematical Biosciences 137: 101, 1996.11, Stark G.: Cardiovasc. Res. 35: 43, 1997.12, Verduyn SC.: J.Am.Coll.Cardiol. 30: 1575, 1997.13, Vaughan Williams E.M.: Control of cardiac rhythm Lippincott-Raven 43p, Chapter 4, 1998.14, Zhang H.T.: J. Biomed. Sci. 7: 100, 2000.15, Varma P.: Can. J. Physiol. Pharmacol. 80: 22, 2002.16, Kaab S.: Eur. Heart J. 24: 649, 2003.
36) Cardioscience 2: 233-243, 1991.Citations:
40
1, Surawicz B.: Cardiovasc. Res. 26: 1021, 1992.2, Bril A.: Pharmacol. 48: 308, 1994.3, Kelso E.J.: Br. J. Pharmacol. 115: 74, 1995.4, Buljubasic N.: Anesthesiol. 85: 1092, 1996.5, Spiers J.P.: Br. J. Pharmacol. 119: 1427, 1996.6, Kelso E.: Eur. J. Pharmacol. 308: 351, 1996.7, Yehia A.R.: Am. J. Physiol. 42: H1, 1997.8, Lanrita K.R.: Can. J. Cardiol.13: 1069, 1997.9, Kelso E.J.: J.Pharmacol. Exp. Ther. 286: 662, 1998.10, Kelso E.J.: Biochemical Pharmacol. 55: 897, 1998.11, Yehia A.R.: CHAOS 9: 916, 1999.12, Kelso E.J.: Eur. J. Pharmacol. 400: 43, 2000.13, Dumotier B.M.: Eur. J. Pharmacol. 422: 137, 2001.
37) Pharmacol. & Toxicol. 71: 52-56, 1992.Citations:
1, Kuller A.H.: Anesthesiology 92: 1713, 2000.
39) Cardioscience 3: 85-89, 1992.Citations:
1, Wettwer E.: Cardiovasc. Res. 27: 1662, 1993.2, Coraboeuf E.: Cardiovasc. Res. 27: 1713, 1993.3, Mubagwa K.: J. Cardiovasc. Electrophysiol. 5: 659, 1994.4, Gross G.J.: Cardiovasc. Res. 29.: 112, 1995.5, Onadid H.: J. Cardiovasc. Pharmacol. 25.: 282, 1995.6, Cheng J.M.: Cardiovasc. Res. 31: 963, 1996.7, Pieske B.: J. Clin. Invest. 98: 764, 1996.8, Montero M.: J. Cardiovasc. Pharmacol. 27: 571, 1996.9, Buljubasic N.: Anesthesiol. 85: 1092, 1996.10, Rusznak Z.: Gen. Physiol. Biophys. 15: 223, 1997.11, Pelzmann B.: Cardiovasc. Res. 38: 424, 1998.12, Richard S.: Cardiovasc. Res. 37: 300, 1998.13, Cheng J.H.: Cardiovasc. Res. 43: 135, 1999.14, Tovar O.H.: Circulation 102: 2886, 2000.
41) Cardioscience 3: 131-144, 1992.Citation:
1, Karhu S.: Eur. J. Pharmacol. 279: 7, 1995.2, Ravens U.: Fundam. Clin. Pharmacol. 10: 321, 1996.3, Howarth F.C.: Pflugers Arch. 431: 713, 1996.4, Fantini E.: Mol. Cell. Biochem. 161: 61, 1996.5, Padrini R.: Pharmacol. Res. 35: 409, 1997.6, Szokodi I.: Circulation 97: 1062, 1998.7, Klockner U.: Eur. J. Neurosci. 11: 4171, 1999.8, Kecskemeti V.: J. Physiol. Pharmacol. 51: 723, 2000.9, Zaritsky J.J.: J. Physiol 533: 697, 2001 .
41
42) Cardioscience 4: 111 - 416, 1993.Citation:
1, Pelzmann B.: Cardiovasc. Res. 38: 424, 1998.2, Mruck S.: J. Nucl. Med. 41: 1587, 2000. 3, Roscoe A.K.: Anaesthesology 92: 1692, 2000.
43) Basic Research Cardiol. 88: 93-102, 1993.Citation:
1, Dalonzo A.J.: Cardiovasc. Res. 28: 924, 1994.2, Fournier A.: Cardiosci. 6: 71, 1995.3, Zhou X.H.: J. Cardiovasc. Electrophysiol. 6: 252, 1995.4, Ytrehus K.: Am. J. Physiol. - Heart Circ. Physiol. 36: H2383, 1994.5, Dalonzo A.J.: Eur. J. Pharmacol. 272: 269, 1995.6, Barry D.M.: Circ. Res. 77: 361, 1995.7, Dawodu A.A.: Int. J. Cardiol. 54: 237, 1996.8, Ogura T.: J. Mol. Cell. Cardiol. 28: 1777, 1996.9, Tavi P.: Br. J. Pharmacol. 118: 407, 1996.10, Thuringer D.: J. Mol. Cell. Cardiol. 28: 387, 1996.11, Brooks R.R.: Proc. Soc. Exp. Biol. Med. 212: 84, 1996.12, Wetzel G.T.: Cardiovasc. Res. 31: E52, 1996.13, Gidhjain M.: Circ. Res. 79: 669, 1996.14, Xu H.D.: J. Gen. Physiol. 108: 405, 1996.15, Shigematsu S.: Basic Res. Cardiol. 92: 123, 1997.16, Yehia A.R.: Am. J. Physiol. 42: H1, 1997.17, Kupiryaov V.V.: NMR In Biomedicine 11: 131, 1998.18, Xu A.X.: Chaos 8: 157, 1998.19, Maryon E. B.: J. Cell. Science 111: 2885, 1998.20, Zaniboni M.: J. Mol. Cell. Cardiol. 30: 2229, 1998.21, Terraciano C. M. N.: J. Physiol. 512: 651, 1998.22, Smith G. L.: Pflügers Arch. 437: 139, 1998.23, Mittelstadt - SW.: Cardiovasc. Drug.Ther.11 : 591, 1997.24, Durat I.: Mol.Cell. Biochem. 175: 253, 1997.25 Liu X.K.: J. Cardiovasc. Pharmacol. 34: 287, 1999.26, Picard S.: J. Cardiovasc. Pharmacol. 34: 162, 1999.27, Huelsing D. J.: Am. J. Physiol. 45: H572, 1999.28, Shorofsky S. R.: Circ. Res. 84: 424, 1999.29, Wilders R.: Circulation 99: 1623, 1999.30, Aasum E.: Cryobiology 38: 243, 1999.31, Li H.: J. Electrocardiology 32: 159, 1999.32, Linz K.W.: Pflügers Arch. 439: 588, 2000.33, Benardeau A.: J. Pharmacol. Exp. Ther. 292: 561, 2000.34, Sharma V.: Am. J. Physiol. 282: H72, 2002.35, Nakajima I.: Circ. J. 66: 87, 2002.36, Kocic I.: Pflügers-Arch. Eur. J. Physiol. 443: 353, 2002.37, Nakajima I.: Circ. J. 66: 87, 2002.
42
38, Farkas A.: Eur. J. Pharmacol. 449: 143, 2002.39, Sundset R.: Can. J. Physiol. Pharmacol. 81: 937, 2003.40, Farkas A.: J. Cardiovasc. Pharmacol. 42: 612, 2003.41, Matsuda H.: Pflügers Arch. Eur. J. Physiol. 448: 54, 2004.
44) Pflügers Arch. Eur. J. Physiol. 423: 158-160, 1993.Citations:
1, Lipp P.: Circ. Res. 74: 979, 1994.2, Bassani J.W.M.: J. Physiol. 476: 279, 1994.3, Bouchard R.A.: Circ. Res. 76: 790, 1995.4, Lopezlopez J.R.: Science 268: 1042, 1995.5, Bassani R.A.: Biophys. J. 68: 2015, 1995.6, Terracciano C.M.N.: Circ. Res. 77: 354, 1995.7, Delbridge L.M.D.: Am. J. Physiol. 39: C192, 1996.8, Levi A.J.: Cardiovasc. Res. 32: 534, 1996.9, Maryon E.B.: J. Cell. Biol. 134: 885, 1996.10, Westerblad H.: Acta Physiol. Scand. 156: 407, 1996.11, Li L.: J. Physiol. 501: 17, 1997.12, Terracciano C.M.N.: J. Physiol. 500: 557, 1997.13, Vornanen M.: Cardiovasc. Res. 33: 611, 1997.14, Terracciano C.M.N.: Pflugers-Arch. 433: 542, 1997.15, Li L.: J. Physiol. 501: 17, 1997.16, Bassani R.A.: Am. J. Physiol. 42: H886, 1997.17, Shannon T.R.: Biophys. J. 73: 1524, 1997.18, Yao A.S.: Circ. Res.: 82: 657, 1998.19, Lancaster MK.: Eur. J. Pharmacol. 339: 97, 1998.20, Ginsburg K.S.: J.Gen.Physiol. 111: 491, 1998.21, Linder M.: 30: 743, 1998.22, Ju J.K.: J.Physiol. 508: 153, 1998.23, Saeki.-T.: Am.J.Physiol. 42: H1984, 1997.24, Sipido K.R.:. Circ.Res. 81: 1034, 1997.25, Lit Win SE.: Circ. Res. 81: 1083, 1997.26, Hobai IA.: Pflügers' Arch. 435: 164, 1997.27, Bers D. M.: NY Acad. Sci. 853: 157, 1998.28, Altimiras J.: J. Exp. Biol. 202: 2531, 1999.29, Hovemadsen L.: Pflügers Arch. 438: 545, 1999.30, Ju Y.K.: Pflügers Arch. 438: 338, 1999.31, Carmeliet E.: Physiol. Rev. 79: 917, 1999.32, Kabbara A.A.: Cell Calcium 25: 227, 1999.33, Bers D.R.: Cardiovasc. Res. 42: 339, 1999.34, Kaprielian R.: J. Physiol. 517: 229, 1999. 35, Egdell R.M.: Cardiovasc. Res. 47: 769, 2000.36, Spencer C.I.: J Mol. Cell. Cardiol. 32: 1285, 2000.37, Piacentino V.: J. Physiol. 523: 533, 2000.38, Litwin S.E.: Am. J. Physiol. C278: H862, 2000.39, Harwood C.L.: J. Exp. Biol. 203: 493, 2000.
43
40, Ritter M.: Am. J. Physiol. C278: H666, 2000.41, Ju Y.K.: J. Physiol. 516: 793, 1999.42, Sipido K.R.: Circulation 102: 2137, 2000. 43, Lukyanenko V.: Biophys. J. 79: 1273, 2000. 44, Terracciano C.M.N.: Cardiovasc. Res. 49: 38, 2001. 45, Litwin S.E.: Circ. Res. 87: 1040, 2000.46, Naqvi R.U.: Int. J. Cardiol. 77: 189, 2001. 47, Milnes J.T.: J. Mol. Cell. Cardiol. 33: 473, 2001. 48, Meszaros J.: Am. J. Physiol. 281: H903, 2001 .49, Rice J.J.: Philos. T Roy Soc. A. 359: 1143, 2001 50, Terracciano C.M.N.: J.Physiol. 533: 165, 2001 .51, Sah R.: J. Physiol. 533: 201, 2001. 52, Davia K.: J. Mol. Cell. Cardiol. 33: 1005, 2001.53, Li Y.X.: J. Physiol. 537: 17, 2001.54, Gray R.P.: J. Physiol. 544: 56P, 2002.55, Shiels H.A.: J. Exp. Biol. 205: 3631, 2002.56, Antoons G.: J. Physiol. 543: 889, 2002.57, Terracciano C.M.N.: Cell Calcium 31: 299, 2002.58, Gyorke S.: Front Biosci. 7: D1454, 2002.59, Sobie E.A.: Biophys. J. 83: 59, 2002.60, Ranu H.K.: J. Mol. Cell. Cardiol. 34: 389, 2002.61, Sipido K.R.: Ann. NY Acad. Sci. 976: 438, 2002.62, Litwin S.E.: Ann. NY Acad. Sci. 976: 446, 2002.63, Terraccino C.: Ann. NY Acad. Sci. 976: 520, 2002.64, Piacentino V.: Circ. Res. 92: 651, 2003. 65, Hove-Madsen L.: Am. J. Physiol. 284: R1330, 2003.66, Heller L.J.: Am. J. Physiol. 284: H1872, 2003.67, Sears C.E.: Circ. Res. 92: E52, 2003.68, Terracciano C.M.N.: Eur. Heart J. 14: 1329, 2003.69, Chorvatova A.: Pflügers Arch. Eur. J. Physiol. 446: 422, 2003.70, Venetucci L.: Circ. Res. 93: 4, 2003.71, Shannon T.R.: Circ. Res. 93: 40, 2003.72, Antoons G.: Circ. Res. 92: 881, 2003.73, Bassani R.A.: Braz. J. Med. Biol. Res. 36: 1717, 2003.74, Swan J.S.: Cardiovasc. Res. 60: 337, 2003.75, Diaz M.E.: Circ. Res. 94: 650, 2004.76, Hinch R.: Biophys. J. 86: 1293, 2004.77, Liew R.: Cardiovasc. Res. 61: 66, 2004.
45) Br. J. Pharmacol. 109: 895-897, 1993.Citation:
1, Roewer N.: Anesthesiol. 82: 947, 1995.2, Lopez M.G.: J. Physiol. 482: 15, 1995.3, Reiser M.A.: Br. J. Pharmacol. 118: 2145, 1996.4, Low A.M.: Can. J. Physiol. Pharmacol. 74: 298, 1996.5, Low A.M.: Clin. Exp. Pharmacol. Physiol. 23: 310, 1996.6, Nunez L.: Eur. J. Neurosci. 8: 192, 1996.
44
7, Villalobos C.: Pflugers Arch. 431: 371, 1996.8, Postlethwaite M.: Br. J. Pharmacol. 129: 1447, 2000.9, Zhao F.L.: Am. J. Physiol. 283: R115, 2002.10, Chorvatova A.: J. Physiol. 544: 61P, 2002.11, Chorvatova A.: Pflügers Arch. Eur. J. Physiol. 446: 422, 2003.
46) Acta Physiol. Scand. 149: 133-142, 1993.Citation:
1, Gross G.J.: Cardiovasc. Res. 29: 112, 1995.2, Wood L.S.: Gene 163: 313, 1995. 3, Tang W.M.: Receptor Channel 3: 175, 1995.4, Park W.K.: Anesthesiol. 84: 1166, 1996.5, Koidl B.: Naunyn-Sch. Arch. Pharmacol. 353: 226, 1996.6, Barry D.M.: Ann. Rev. Physiol. 58: 363, 1996.7, Courtemanche M.: Am.J.Physiol. 44: H301, 1998.8, Hoppe U.C.: Cardiovasc. Res. 38: 788, 1998.9, Pelzman B.: Cardiovasc. Res. 38: 424, 1998.10, Schaffer P.: Pflügers Arch. 436: 457, 1998.11, Opthof T.: Cardiovasc. Res.: 38: 537, 1998.12, Schaffer P.: Cardiovasc. Res. 43: 332, 1999.13, Bailly P.: Circulation 98: 2753, 1998.14, Wang Z. G.: Circulation 98: 2422, 1998.15, Nerbonne J. M.: J. Neurobiol. 37: 37, 1998.16, Volk T.: J. Physiol. 519: 841, 1999.17, Schaffer P.: Cardiovasc. Res. 43: 332, 1999.18, Liang J.: Acta Pharmacol. Sin. 20: 1005, 2000.19, Gallego M.: Diabetes Metab. Res. 17: 304, 2001.20, Schram G.: Modulator 15: 5, 2001.21, Nerbonne J.M.: Handbook of Physiology Section 2. The Cardiovascular System Oxford Univ. Press 2001, 568p.22, Melnyk P.: Am. J. Physiol. 283: H1123, 2002.23, Finley M.R.: J. Vet. Intern. Med. 17: 473, 2003.24, Hatano N.: Br. J. Pharmacol. 139: 533, 2003.
47) Eur. J. Pharmacol. 240: 127-137, 1993.Citations:
1, Amos G.J.: N-Sch. Arch. Pharmacol. 350: 426, 1994.2, Feldman A.M.: Cor. Art. Dis. 5: 107, 1994.3, Antonaccio M.J.: Electropharmacological control of arrhythmias. 465, Chapter 33. Futura Co 1994.4, Feldman D.A.: Clin. Cardiol. 18: 28, 1995.5, Kass D.A.: Am. J. Cardiol. 78: 652, 1996.6, Chi J.F.: Br. J. Pharmacol. 118: 503, 1996.7, Focaccio A.: Circulation 93: 817, 1996.8, Yang T.: J. Pharmacol. Exp. Ther. 280: 1170, 1997.
45
9, Editorial Material Current Problems in Cardiology 21: 527, 1996.10, Eto K.: Cardiovasc. Res.: 38: 685, 1998.11, Hata T.: Heart Vessels 13: 114, 1998.12, Toivonen L.: J. Cardiovasc. Pharmacol. 35: 664, 2000.13, Cheng J.H.: Acta Pharmacol. Sin. 22: 193, 2001.
48) Eur. J. Med. Chem. 28: 185-193, 1993.Citation:
1, Eltombary A. A.: Farmaco. 54: 486, 1999.2, Chalina E. G.: Eur. J. Med. Chem. 33: 975, 1999.
49) J. Cardiovasc. Pharmacol. 24: 559-565, 1994.Citation:
1, Stark U.: J. Cardiovasc. Pharmacol. 27: 125, 1996.2, Stark U.: Cardiovasc. Drugs Ther. 10: 531, 1996.3, Klapperstuck M.: Pharmazie 54: 61, 1999.
51) Gen. Pharmacol. 25: 1661-1666, 1994.Citation:1, Freitas E.M.S.: Histochem. Cell. Biol. 116: 525, 2001.
54) J. Physiol. (London) 486: 581-591, 1995.Citation:
1, Vornanen M.: Mol. Cell. Biochem. 164: 5, 1996.2, Terracciano C.M.N.: Biophys. J. 72: 1319, 1997.3, Vornanen M.: Am. J. Physiol. 41: R1432, 1997.4, Wang S.Y.: J. Mol. Cell. Cardiol. 29: 1277, 1997.5, Gomez A.M.: Science 276/5313: 800, 1997.6, Cook S.J.: Pflugers Arch. 433: 542, 1997.7, Terracciano C.M.N.: Pflugers Arch. 433: 542, 1997.8, Lancaster MK.: Eur. J.Pharmacol. 339: 97, 1998.9, Vornanen M.: Journal of Experimental Biology 204: 533, 1998.10, Su M.J.: Br.J.Pharmacol. 122: 1285, 1997.11, Blaustein M. P.: Physiological Rev. 79: 763, 1999.12, Hove-Madsen L.: Am. J. Physiol. 44: R2070, 1999.13. Delgado C.: J. Mol. Cell. Cardiol. 31: 1783, 1999.14, Bers D.M.: Circ. Res. 87: 275, 2000.15, Zavecz J.H.: Am. J. Physiol. 279: G28, 2000.16, Spencer C.I.: J. Mol. Cell. Cardiol. 32: 1285, 2000.17, Baartscheer A.: J. Mol. Cell. Cardiol. 32: 1025, 2000.18, Satoh H.: Circulation 101: 1441, 2000.19, Tweedie D.: J. Mol. Cell. Cardiol. 32: 261, 2000.20, McIntosh M.A.: Cardiovasc. Res. 45: 397, 2000.21, Isenberg G.: Cardiovasc. Res. 49: 1-6, 2001. 22, Hobai I.A.: Circulation 103: 1577, 2001.
46
23, Schmidt H.D.: Res. Exp. Med. 200: 107, 2001.24, Sipido K.R.: Cardiovasc. Res. 53: 782, 2002.25, Shiels H.A.: J. Exp. Biol. 205: 3631, 2002.26, Vornanen M.: Comp. Biochem. Physiol. A. 132: 827, 2002.27, Sobie E.A.: Biophys. J. 83: 59, 2002.28, Crozatier B.: FASEB J. 16: 653, 2002.29, Schillinger W.: Cardiovasc. Res. 57: 996, 2003.30, Chorvatova A.: Pflügers Arch. Eur. J. Physiol. 446: 422, 2003.31, Guo J.: J. Physiol. 547: 797, 2003.32, Zhang H.: Int. J. Bifurcat. Chaos. 13: 3535, 2003.33, Hinch R.: Biophys. J. 86: 1293, 2004.34, Xu L.: Biophys. J. 86: 797, 2004.
55) J. Cardiovasc. Pharmacol. 26: S32-S44, 1995.Citation:
1, Sundberg S.: Am. J. Cardiol. 75: 1061, 1995.2, Verdonck L.: Cardiovasc. Drug Rev. 14: 185, 1996.3, Pagel P.S.: Cardiovasc. Drug. Rev. 14: 286, 1996.4, Édes I.: Cardiologica Hung. 26: (S6) 3, 1997.5, Eto K.: Cardiovasc. Res. 38: 685, 1998.6, Mathew L.: Drugs and Aging 12: 191, 1998.7, Thormann J.: Herz Kreislauf 30: 382, 1998.8, Uemura H.: Eur. J. Pharmacol. 383: 361, 1999.9, Stowe D.F.: Am. J. Physiol. C277: H2321, 1999.10, Toivonen L.: J. Cardiovasc. Pharmacol. 35: 664, 2000.11, Wang G.X.: J. Pharmacol. Exp. Ther. 293: 501, 2000.12, Toller W.G.: Drug Future 25: 563, 2000.13, Fujita S.: J. Mol. Cell. Cardiol. 32: 1647, 2000.14, Denac H.: Naunyn-Sch. Arch. Pharmacol. 362: 453, 2000. 15, Li M.X.: Biochemistry 39: 8782, 2000. 16, Figgitt D.P.: Drugs 61: 613, 2001.17, Lehtonen L.A.: Exp. Opin. Inv. Drug10: 955, 2001.18, Wang X.: J. Biol.Chem. 276: 25456, 2001.19, duToit P.: Heart 86: 81, 2001. 20, Hu T.C.C.: Magnet. Reson Med. 46: 884, 2001.21, Wang X.: J. Biol. Chem. 277: 31124, 2002.22, Narita T.: J. Cardiovasc. Pharmacol. 42: 364, 2003.23, Greenberg B.: Eur. J. Heart Fail. 5: 13, 2003.
56) Cardiovasc. Res. 31: 246-248, 1996.Citation:
1, Tessier S.: Br. J. Pharmacol. 122: 291, 1997.2, Doggrell S.A.: Current Research in Ion-channel Modulators 3: 77, 1998.3, Hermann H. P.: J. cardiovasc. Pharmacol. 32: 969, 1998.
47
4, Fischbach P. S.: J. Cardiovasc. Pharmacol. 34: 212, 1999.5, Tribulova N.: Mol. Cell Biochem. 210: 75, 2000.6, Doggrell S.A.: Expert Opin. Inv. Drug 10: 129, 2001.7, Barrett T.D.: Br. J. Pharmacol. 132: 1493, 2001.8, Fischbach P.S.: J. Cardiovasc. Electrophys. 12: 1138, 2001.9, Dorian P.: J. Cardiovasc. Pharmacol. Ther. 8.Suppl.1: S27, 2003.10, Sarraf G.: Br. J. Pharmacol. 139: 1389, 2003.
57) Gen. Pharmacol. 27: 69-71, 1996.Citation:1, McCleane G.: Pain Clinic 13: 83, 2001. 2, Huang Y.F.: J. Pharmacol. Sci. 92: 180, 2003.
58) Gen. Pharmacol. 27: 551-556, 1996.Citation:
1, Eto K.: Cardiovasc. Res.: 38: 685, 1998.2, Lancaster MK.: Eur.J.Pharmacol 339: 97, 1998.3, Yokoshiki H.: J. Pharmacol. Exp. Ther. 283: 375, 1997.4, Toivonen L.: J. Cardiovasc. Pharmacol. 35: 664, 2000.5, Ajiro Y.: Eur. J. Pharmacol. 435: 27, 2002.6, Bodi A.: Gen. Physiol. Biophys. 22: 313, 2003.
60) J.Cardiovasc. Pharmacol. Therapeut. 1: 133-140, 1996.Citation:
1, Eto K.: Cardiovasc. Res.: 38: 685, 1998.
61) Br. J. Pharmacol. 117: 1181-1186 1996.Citation:
1, Singh B.N.: J. Cardiovasc. Pharmacol. Therapeut. 1: 265-270, 1996.2, Kodama I.: Cardiovasc. Res. 35: 13, 1997.3, Bosch R.F.: Cardiovasc. Res.: 38: 441, 1998.4, Carmeliet E.: Progress in Biophys and Mol. Biol. 70: 1, 1998.5, Gray D.F.: J. Pharmacol. Exp. Ther. 284: 75, 1998.6, Sicouri S.: J. Cardiovasc. Electrophys. 8: 1269, 1997.7, Vaughan Williams E.M.: Control of cardiac rhythm Lippincott-Raven 43p, Chapter 4, 1998.8, Kiehn J.: N-S. Arch. Pharmacol. 359: 212, 1999.9, Moreau D.: Mol. Cell. Biochem. 194: 291, 1999.10, Bosch R. F.: J. Pharmacol. Exp. Ther. 289: 156, 1999.11, Bosch R. F.: J. Cardiovasc. Pharmacol. 33: 762, 1999.12, Kodama I.: Am. J. Cardiol. 84: 20R, 1999.13, Watanabe Y.: Br. J. Pharmacol. 131: 80, 2000.14, Lacroix D.: PACE 23: 1133, 2000.15, Aimond F.: J. Pharmacol. Exp. Ther. 292: 415, 2000.
48
16, Nakaya H.: Br. J. Pharmacol. 131: 1363, 2000.17, Di Matola T.: J. Clin. Endocr. Metab. 85: 4323, 2000.18, Lu Z.B.: Circulation 104: 951, 2001.19, Kamiya K.: Circulation 103: 1317, 2001.20, Kobayashi S.: Eur. J. Pharmacol. 430: 149, 2001.21, Gbadebo T.D.: Circulation 105: 770, 2002.22, Watanabe Y.: Jpn. J. Pharmacol. 90: 21, 2002.23, Varbiro G.: Biochem. Pharmacol. 65: 1115, 2003.24, Gautier P.: J. Cardiovasc. Pharmacol. 41: 191, 2003.25, Mubagwa K.: Cardiovasc. Drug Rev. 21: 216, 2003.26, Varbiro G.: J. Pharmacol. Exp. Ther. 307: 615, 2003.27. Trachsel D.: Toxicol. Appl. Pharmacol. 195: 113, 2004.
62) J. Comp. Physiol. 166: 150-156, 1996.Citation:
1, Anand I.S.: Circulation 96: 3974, 1997.2, Doggrell S.A.: Current Research in Ion Channel Modulators 3: 77, 1998.3, Leblanc N.: J. Physiol. 511: 533, 1998.4, Carpention R.G.: Life Sci. 63: 859, 1998.5, Harwood C.L.: J. Exp. Biol. 203: 493, 2000.6, Edwards R.: Basic Res. Cardiol. 97: 374, 2002.7, Gautier P.: J. Cardiovasc. Pharmacol. 41: 191, 2003.
63) Clin. Physiol. 16: 339-351, 1996.Citation:
1, Wu T. J.:J. Cardiovasc. Electrophys. 10: 1077, 1999.2, Davey P.: Acta Physiol. Scand. 171: 17, 2001.3, Simurda J.: Eur. Biophys. J. Biophy. 30: 500, 2001.4, Bernus O.: Physiol. Rev. E. 68: art.no.021917, 2003.
64) Acta Physiol. Scand. 158: 143-153, 1996. Citation:1, Iravanian S.: Am. J. Physiol. 285: H449, 2003.2, Bursac N.: Tissue Eng. 9: 1243, 2003.
65) J. Pharmacol. Exp. Ther. 277: 1215-1220, 1996.Citation:1, Link M.S.: Circulation 100: 413, 1999.2, Ooie T.: J. Cardiol. Fail. 6: 250, 2000.3, Coetzee W.A.: Eur. J. Pharmacol. 402: 263, 2000. 4, Svorc P.: Physiol. Res. 49: 711, 2000.5, del Valle H.F.: Cardiovasc. Res. 50: 474, 2001. 6, Das B.: Naunyn-Sch. Arch. Pharmacol. 364: 383, 2001.7, Das B.: Pharmacology 63: 134, 2001.
49
8, Negroni J.A.: Basic Res. Cardiol. 97: 55, 2002.9, Billman G.E.: Drug Develop. Res. 55 Spec. Iss.: 59, 2002. 10, Yazar A.: Pharmacol. Res. 45: 183, 2002.11, Das B.: Eur. J. Pharmacol.: 437: 165, 2002.12, Posa I.: Arzneimittel-Forsch. 52: 552, 2002.13, Das B.: Method Find. Exp. Clin. 25: 97, 2003.14, Das B.: Pharmacol. Res. 47: 447, 2003.15, Das B.: Pol. J. Pharmacol. 55: 771, 2003.
66) J. Cardiovasc. Pharmacol. Therapeut. 1: 287-296, 1996.Citation:
1, Sicouri S.: J. Cardiovasc. Electrophysiol. 8: 1269, 1997.2, Singh B.N.: J. Cardiovasc. Pharmacol. Therapeut. 1: 265-270, 1996.3, Carmeliet E.: Progress in Biophys and Mol. Biol. 70: 1, 1998.4, Merot J.: Cardiovasc. Res. 44: 303, 1999. 5, Maltsev V.A.: J. Mol. Cell. Cardiol. 33: 923, 2001.6, Singh B.N.: J. Cardiovasc. Pharmacol. Ther. 8.Suppl.1: S13, 2003.7, Resnik A.V.: Kardiologiya 43: 76, 2003.
68) Gen. Pharmacol. 29: 275-280, 1997. Citation:
1, Resnik A.V.: Kardiologiya 43: 76, 2003.
69) Naunyn-Schmiedeberg Arch. Pharmacol. 355: 398-405, 1997.Citation:
1, Beatch G.N.: Drug Develop. Res. 55: 45, 2002.
70) Exp. Clin. Cardiol. 2: 205-209, 1997.Citation:1, Simurda J.: Eur. Biophys. J. Biophy. 30: 500, 2001.
71) Exp. Clin. Cardiol. 2: 37-40, 1997.Citation:
1, Christie G.: Eur. J. Pharmacol. 373: 223, 1999.
72) J.Cardiovasc. Pharm. Therepeut. 2: 273-284, 1997.Citation:
1, Singh B.N.: Am. J. Cardiol. 81: 6A, D3, 1998.2, Singh B.N.: J. Cardiovasc. Electrophysiol. 10: 283, 1999.3, Fischbach P.S.: J. Cardiovasc. Pharmacol. 34: 212, 1999.4, Camm A.J.: EUROPACE 1. Suppl.C: C16-C22, 2000. 5, Doggrell S.A.: Expert Opin. Inv. Drug 10: 129, 2001.
50
6, Castro A.: PACE 25: 249, 2002.7, Freestone B.: Expert. Opin. Inv. Drug. 13: 151, 2004.
73) Med. Res. Rev. 17: 427-451, 1997.Citation:
1, Herman Z.S.: Pol. J. Pharmacol. 51: 201, 1999.2, Benardeau A.: J. Pharmacol. Exp. Ther. 292: 561, 2000.3, De Benedetti P.G.: J. Mol. Struct. Theochem. 503: 1, 2000.4, Chang G.J.: Br. J. Pharmacol. 136: 459, 2002.5, Kluczyk A.: Curr. Med. Chem. 9: 1871, 2002.6, Yamreudeewong W.: Drug Safety 26: 421, 2003.
76) Int. J. Quant. Chem. 69: 21-30, 1998. Citation:
1, Gohda K.: J. Chem. Inf. Comp. Sci. 41: 196, 2001.
77) PACE 21: 147-150, 1998.Citation:
1, Satoh Y.: Jpn. J. Pharmacol. 83: 327, 2000.2, De Ponti F.: Eur. J. Clin. Pharmacol. 57: 185, 2001.3, Khan I.A.: Am. Heart J. 143: 7, 2002.4, Milberg P.: J. Pharmacol. Exp. Ther. 303: 218, 2002.5, Zeltser D.: Medicine 82: 282, 2003.6, Takahara A.: Eur. J. Pharmacol. 476: 115, 2003.
78) Naunyn-Sch. Arch. Pharmacol. 357: 268-275, 1998Citation:
1 Yan G.X.: Circulation 100: 1660, 1999.2 Shimizu W.: J. Cardiovasc. Electrophys. 11: 1320, 2000.3 Satoh H.: Eur. J. Pharmacol. 407: 123, 2000.4 Witchel H.J.: Clin. Exp. Pharmacol. 27: 753, 2000.5 Miyamoto S.: Eur. J. Pharmacol. 400: 263, 2000.6 Hancox J.: Heart 84: 14, 2000.7 Paul A.A.: J. Physiol. 523: 158P, 2000.8, Sanchez-Chapula J.A.: J. Pharmacol. Exp. Ther. 290: 515, 1999.9, Paul A.A.: Biochem. Biophys. Res. Comm. 280: 1243, 2001.10, Yang T.: J. Cardiovasc. Pharmacol. 38: 737, 2001.11, Belhassen B.: PACE 25: 1634, 2002.12, Yoshida H.: Circ. J. 66: 857, 2002.13, Paul A.A.: Br. J. Pharmacol. 136: 717, 2002.
51
14, Hanada E.: J. Pharm. Pharmacol. 55: 995, 2003.15, Ridley J. M.: Biochem. Biophys. Res. Comm. 306: 388, 2003.16, Takagi M.: Heart 89: 169, 2003.
80) Acta Physiol. Scand. 164: 181-190, 1998.Citation:
1, Crick S.J.: J. Anat. 195: 359, 1999. 2, Wolk R.: Pharmacol. Ther. 84: 207, 1999.3, Antzelevitch C.: J. Cardiovasc. Electrophysiol. 10: 1124, 1999.4, Antzelevitch C.: Eur. Heart J. 3 Suppl. K: K2, 2001. 5, Antzelevitch C.: Cardiovasc. Res. 50: 426, 2001 .6, Taggart P.: Cardiovasc. Res. 50: 454, 2001 .7, Antzelevitch C.: Curr. Opin. Cardiol. 16: 1, 2001.8, Antzelevitch C.: Basic Res. Cardiol. 96: 517, 2001.9, Antzelevitch C.: Curr. Opinion Cardiol. 17: 43, 2002.10, Carmeliet E.: Cardiac Cellular Electrophysiology. Kluwer Acad. Publishers. 421pp, 2002.11, Taggart P.: Prog. Biophys. Mol. Bio. 82: 243, 2003.
81) Cardiol. Hung. 27: 155-164, 1998.Citation:
1., Fazekas T.: Cardiol. Hung. 29: 159, 1999.
82) Cardiovasc. Res. 40: 508-515, 1998.Citation:
1, Veldkamp M. W.: Cardiovasc. Res. 40: 433, 1998.2, Crumb W.: Pharmacentical Science and Technology Today. 2: 270, 1999.3, Schaffer P.: Cardiovasc. Res. 43: 332, 1999.4, Vereecke J.: Pflügers Arch. 439: 739, 2000.5, Tsui Y.: Cardiovasc. Res. 48: 300, 2000.
6, Kaab S.: Eur. Heart J. Suppl.3K:: K31, 2001 . 7, Lande G.: Cardiovasc. Res. 50: 328, 2001.
8, Ideker R.E.: Circ. Res. 89: 1089, 2001.9, Kaab S.: Eur. Heart J. Suppl.3(K).: K31, 2001. 10, Nerbonne J.M.: Handbook of Physiology Section 2. The
Cardiovascular System Oxford Univ. Press 2001, 568p.
11, Li Y.: Cardiovasc. Drug Ther. 16: 317, 2002. 12, Bertaso F.: Basic Res. Cardiol. 97: 424, 2002. 13, Thomas G.P.: J. Cardiovasc. Pharmacol. 41: 140, 2003. 14, Carmeliet E.: Cardiac Cellular Electrophysiology. Kluwer Acad.
Publishers. 421pp, 2002.15, Kathofer S.: Naunyn-Sch. Arch. Pharmacol. 368: 119, 2003.
52
16, Tosaka T.: J. Pharmacol. Exp. Ther. 306: 980, 2003.17, Farkas A.: J. Cardiovasc. Pharmacol. 42: 612, 2003.18, ten Tusscher K.H.W.J.: Am. J. Physiol. 286: H1573, 2004. 19, Cheng J.H.: Acta Pharmacol. Sin. 25: 137, 2004.
83) Acta Physiol. Scand. 163(2):139-147, 1998.Citation:1, Simurda J.: Eur. Biophys. J. Biophy. 30: 500, 2001.2, Sun W.: J. Cardiovasc. Pharmacol. 39: 677, 2002.3, Fenton F.H.: Chaos 12: 852, 2002.4, Walker M.L.: Cardiovasc. Res. 57: 599, 2003.5, Bernus O.: Physiol. Rev. E. 68: art.no. 021917, 2003.
84) Med. Res. Rev. 19: 249-269, 1999.Citation:
1, Estrada E.: Sar. Qsar. Environ. Res. 11: 55, 2000.2,Quinones C.: Quant. Struct. Act. Rel. 19: 448, 2000.3, Tetko I.V.: J. Med. Chem. 44: 2411, 2001.4, Burbidge R.: Comput. Chem. 26: 5, 2001.5, Buchwald P.: Drug Future 27: 577, 2002.6, Landavazo D.G.: Biosystems 65: 37, 2002.7, Turner J.V.: J. Comput. Chem. 24: 891, 2003.8, Tong W.: Environ. Toxicol. Chem. 22: 1680, 2003.9, Halberstam N.M.: USP. Khim. 72: 706, 2003.10, Livingstone D.J.: Qsar Comb. Sci. 22: 510, 2003.11, Prabhakar Y.S.: Qsar. Comb. Sci. 22: 583, 2003.
85) Gen. Pharmacol. 32: 329-333, 1999.Citation:
1, Faivre J.F.: Eur. J. Pharmacol. 383: 215, 1999.
86) Cardiovasc Drugs Ther. 13: 491-505, 1999Citation:
1, Nerbonne J.M.: Handbook of Physiology Section 2. The Cardiovascular System Oxford Univ. Press 2001, 568p.
90) J. Physiol. (London) 523: 67-81, 2000.Citation:
1, Rogers J.M.: J. Cardiovasc. Electrophysiol. 11: 1364, 2000.2, Nattel S.: Cardiovasc. Res. 48: 188, 2000. 3, Haverkamp W.: Cardiovasc. Res. 47: 219, 2000.
53
4, Haverkamp W.: Eur. Heart J. 21: 1216, 2000.5, Dorian P.: Europace 2: 277, 2000.6, Han W.: Am. J. Physiol. C 280: H1075, 2001. 7, Caballero R.: Mol. Pharmacol. 59: 825, 2001. 8, Lu Z.B.: Circulation 104: 951, 2001 .9, Kocic I.:Cardiovasc. Res.51: 59, 2001 .10, Magyar J.: Naunyn-Sch. Arch. Pharmacol. 363: 604, 2001 .11, Pham T.V.: Circulation 103: 2207, 2001.12, Lande G.: Cardiovasc. Res. 50: 328-334, 2001.13, Hoppe U.C.: P. Natl. Acad. Sci. USA 98: 5335, 2001. 14, Sun Z.Q.: J. Cardiovasc. Electrophys. 12: 472, 2001 .15, Banyasz T.: Naunyn-Sch. Arch. Pharmacol. 363: 383, 2001.16, Gerlach U.: Drug Future 26: 473, 2001.17, Kocic I.: Pfügers Arch. Eur. J. Physiol. 443: 353, 2002.18, Fox J.J.: Am. J. Physiol. 282: H516, 2002.19, Fox J. J.: Circ. Res. 90: 289, 2002.20, Burashnikov A.: J. Cardiovasc. Electr. 13: 172, 2002.21, Bauer A.: J. Cardiovasc. Pharmacol. 39: 460, 2002.22, Chiang C.E.: Cardiovasc. Res. 55: 290, 2002.23, Wickenden A.D.: Pharmacol. Ther. 94: 157, 2002.24, Lynch J.J.: J. Pharmacol. Exp. Ther. 302: 283, 2002.25, Han W.: Am. J. Physiol. 283: H2495, 2002.26, Lu H.R.: Eur. J. Pharmacol. 452: 183, 2002.27, Cabo C.: Am. J. Physiol. 284: H372, 2003.28, Nerbonne J.M.: Handbook of Physiology Section 2. The Cardiovascular System Oxford Univ. Press 2001, 568p.29, Carmeliet E.: Cardiac Cellular Electrophysiology. Kluwer Acad. Publishers. 421pp, 2002.30, Stump G.L.: J. Cardiovasc. Pharmacol. 42: 105, 2003.31, Seebohm G.: Mol. Pharmacol. 64: 70, 2003.32, Volders P.G.A.: Circulation 107: 2753, 2003.33, Bányász T.: Curr. Med. Chem. 11: 45, 2004.34, Salata J.J.: Curr. Med. Chem. 11: 29, 2004.35, Stengl M.: J. Physiol. 551: 777, 2003.
36, Curtis M.J.: Cardiovasc. Res. 61: 651, 2004. 37, Nakashima H.: Cardiovasc. Res. 61: 705, 2004.38, Cheng J.H.: Acta Pharamcol. Sin. 25: 137, 2004.
91) Gen Pharmacol. 34: 85-93, 2000.Citation:
1, Castro A.: PACE 25: 249, 2002.
92) Eur. J. Pharmacol. 404: 181-190, 2000.Citation:
54
1, Beatch G.N.: Drug. Develop. Res. 55.Spec:Iss. 45, 2002.
94) Pflüg. Arch. Eur. J. Physiol. 441: 144-149, 2000.
1, Carmeliet E.: Cardiac Cellular Electrophysiology. Kluwer Acad. Publishers. 421pp, 2002.2, Shimoni Y.: Am. J. Physiol. 284: H1168, 2003.3, Finley M.R.: J. Vet. Intern. Med. 17: 473, 2003.4, Lehmann M.H.: Am. J. Med. 115: 732, 2003.
96) Br. J. Pharmacol. 132: 101-110, 2001.
Citation:1, Kang J.S.: J. Pharmacol. Exp. Ther. 299: 290, 2001.2, Lu Z.B.: Circulation 104: 951, 2001. 3, Sun Z.Q.: J. Cardiovasc. Electrophysiol. 12: 1205, 2001.4, Yan G.X.: Expert. Opin. Ther. Pat. 12: 633, 2002.5, Lu H.R.: Eur. J. Pharmacol. 452: 183, 2002.6, Wickenden A.D.: Pharmacol.. Therapeut. 94: 157, 2002.7, Lynch J.J.: J. Pharmacol. Exp. Ther. 302: 283, 2002. 8, Gluais P.: J. Cardiovasc. Pharmacol. 41: 506, 2003. 9, Liu X.K.: Cardiovasc. Res. 57: 28, 2003.10, Stengl M.: J. Physiol. 551: 777, 2003.11, Stump G.L.: J. Cardiovasc. Pharmacol. 42: 105, 2003.12, Volders P.G.A.: Circulation 107: 2753, 2003.13, Cahill S.A.: J. Pharmacol. Exp. Ther. 308: 59, 2004.14, Bányász T.: Curr. Med. Chem. 11: 45, 2004.15, Salata J.J.: Curr. Med. Chem. 11: 29, 2004.16, Nakashima H.: Cardiovasc. Res. 61: 705, 2004.17, Cheng J.H.: Acta Pharmacol. Sin. 25: 137, 2004.
97) Cardiovasc. Res. 49: 790-797, 2001.Citation:
1, Lu Z.B.: Circulation 104: 951, 2001.2, Sun Z.Q.: J. Cardiovasc. Electrophysiol. 12: 1205, 2001.3, Li Y.: Cardiovasc. Drug Ther. 16: 317, 2002.4, Han W.: Am. J. Physiol. 283: H2495, 2002.5, Lynch J.J.: J. Pharmacol. Exp. Ther. 302: 283, 2002.6, Stengl M.: J. Physiol. 551: 777, 2003.7, Ehrlich J.R.: J. Physiol. 551: 801, 2003.8, Finley M.R.: J. Vet. Intern. Med. 17: 473, 2003. 9, Stump G.L.: J. Cardiovasc. Pharmacol. 42: 105, 2003.
55
10, Volders P.G.A.: Circulation 107: 2753, 2003.11, tenTusscher K.H.W.J.: Am. J. Physiol. 286: H1573, 2004.12, Cheng J.H.: Acta Pharmacol. Sin. 25: 137, 2004.
99) Br. J. Pharmacol. 133: 625-634, 2001.Citation:
1, Sun W.: J. Cardiovasc. Pharmacol. 39: 677, 2002.2, Nattel S.: Drugs 62: 2377, 2002.3, McMurray J.J.V.: Heart 88.Suppl.2: 40, 2002.
4, Bril A.: Curr. Opin. Pharmacol. 2: 154, 2002.5, Gautier P.: J. Cardiovasc. Pharmacol. 41: 191, 2003.6, Nemec J.: Expert Opin. Inv. Drug 12: 435, 2003.7, Lalevee N.: J. Cardiovasc. Electrophysiol. 14: 885, 2003.8, Roden D.M.: PACE 26: 2340, 2003.9, Roden D.M.: J. Cardiovasc. Electrophys. 14: 1389, 2003.10, Thomas D.: Br. J. Pharmacol. 140: 996, 2003.11, Mubagwa K.: Cardiovasc. Drug Rev. 21: 216, 2003.12, Damy T.: Fund. Clin. Pharmacol. 18: 113, 2004.
100) J. Cardiovasc. Electrophysiol. 12: 1204-1205, 2001.Citation:
1, Volders P.G.A.: Circulation 107: 2753, 2003.2, Nakashima H.: Cardiovasc. Res. 61: 705, 2004.
103) Br. J. Pharmacol. 137: 361-368, 2002.Citation:
1, Nattel S.: J. Mol. Cell. Cardiol. 35: 1395, 2003.2, Ehrlich J.R.: J. Biol. Chem. 279: 1233, 2004.
104) J. Mol. Structure (Theochem.) 585: 167-179, 2002.Citation:
1, Mandity I.M.: J. Mol. Struct.-Theochem. 666: 143, 2003.2, Suvire F.D.: J. Mol. Struct.-Theochem. 666: 455, 2003.
113) Chem. Phys. Letters 365: 542-551, 2002.Citation:
1, Ceci M.L.: J. Mol. Struct. THEOCHEM. 631: 277, 2003.
56
119) Cardiovasc. Res. 58: 66-75, 2003.Citation:
1, Akar F.G.: Circ. Res. 93: 638, 2003.2, Cordeiro J.M.: Am. J. Physiol. 286: H1471, 2004.
127) Physiol. Genomics 12: 97-112, 2003.Citation:
1, Asano Y.: Nat. Genet. 36: 123, 2004.2, Yung C.K.: Genomics 83: 281, 2004.
129) Eur. J. Pharmacol. 470: 163-170, 2003. Citation:
1, Graul A.I.: Drug Future 28: 565, 2003.
130) Am. J. Physiol. 285: H1641-H1649, 2003.Citation:
1, Nakashima H.: Cardiovasc. Res. 61: 705, 2004.2, Loussouarn G.: EMBRO J. 22: 5412, 2003.
KÖNYVFEJEZETEKRE
1) New antiarrhythmic agent with positive cardiac actions (GYKI-38233), in :Advances in pharmacological research and practice. (Könyvfejezet)Citations:
1, Kodama I.: J. Cardiol. Pharmacol. 13.: 616, 1989.2, Miyamoto J.: Br. J. Pharmacol. 104.: 25, 1991.3, Kotake H.: J. Electrocardiol. 25.: 53, 1992.
3) Role of dispersion of repolarization, Chapter 9. in: Advances in Cardiac
57
Electrophysiology and Arrhythmias. (Könyvfejezet)Citations:
1, Gillis A.M.: Sleep 14.: 346, 1991.2, Duan J.: J. Cardiol. Pharmacol. 19.: 593, 1992.
4) Effect of antiarrhythmic drugs on membranechannels, in: Advances in Cardiac Electrophysiology and Arrhythmias.(Könyvfejezet)Citation:
1, Fazekas T.: Acta Phys. Hung. 81: 59, 1993.2, Fazekas T.: Orvosképzés 68: 99, 1993.3, Fazekas T.: Acta Phys. Hung. 81: 289, 1993.4, Fazekas T.: Cardiologica Hung. 22: 35, 1993.5, Fazekas T.: Cardiologica Hung. 22: 17, 1993.6, Fazekas T.: Am. Heart J. 127: 345, 1994.7, Fazekas T.: Acta Phys. Hung. 82: 201, 1994.8, Maxonsage A.: Am. J. Vet. Res. 59: 615, 1998.
ABSZTRAKTOKRA
5) J. Mol. Cell. Cardiol. 19.Suppl.3.: S39, 1987. (Absztrakt)Citation:
1, Ohmura T.: J. Pharmacol. Exp. 254, 696, 1990.
7) J. Mol. Cell. Cardiol. 19.Suppl.3.: S102, 1987. (Absztrakt)Citation:
1, Shibata S.: Gen. Pharmacol. 20.: 303, 1989.2, Miyamoto J.: Br. J. Pharmacol. 104.: 25, 1991.3, Hashimoto K.: J. Cardiol. Pharmacol. 17.: 336, 1991.4, Hashimoto K.: Cardiol. Drug Res. 9.: 413, 1991.
X. Congress of IUPHAR Sydney, 1987. (Absztrakt)Citation:
1, Miyamoto J.: Br. J. Pharmacol. 104: 25, 1991.2, Hashomoto K.: J. Cardiovasc. Pharmacol. 17.: 336, 1991.3, Kodama J.: J. Cardiovasc. Pharmacol. 13.: 616, 1989.4, Shibata S.: Gen. Pharmacol. 20.: 303, 1989.
8) Pharmacol. Res. Comm. 30.: 71, 1988. (Absztrakt)Citation:
58
1, Feher G.: Eur. J. Pharmacol. 183.: 1769, 1990.2, Valko I.: Pharmazie 45.: 290, 1990.
15) J. Mol. Cell. Cardiol. 22.Suppl.1: S16, 1990. (Absztrakt)Citation:
1, Liu T.F.: Meth. Find. E. 14.: 157, 1992.2, Zhou Y.Y.: Acta Pharmacol. Sin. 16: 261, 1995.
29) J. Mol. Cell. Cardiol. 26: 328, 1994. (Absztrakt)Citations:
1, Verdonck L.: Cardiovasc. Drug Rev. 14: 185, 1996.2, Eto K.: Cardiovasc. Res. 38: 685, 1998.
45) J.Mol.Cell. Cardiol: 27: A197, 1995. (Absztrakt)Citation:
1, Nánási P.P.: Cardiovasc. Drug Review 15: 314, 1997.
62) Naunyn Schmiedebergs' Arch 354: R7, 1997. (Absztrakt)Citation:
1, Nánási P.P.: Cardiovasc. Drug. Rew.: 15: 314, 1998.
82) PACE 22: 762, 1999. (Absztrakt)Citation:
1, Volders P.G.A.: Circulation 100: 2455, 1999.
99) Circulation 100: I-495, 1999.
1, Sun Z.Q.: J. Cardiovasc. Electrophysiol. 12: 1205, 2001.
100) PACE 23: 661, 2000. (Absztrakt)Citation:
1, Dorian P.: Europace 2: 277, 2000.
59
